Page last updated: 2024-11-04

carprofen

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

Carprofen is a nonsteroidal anti-inflammatory drug (NSAID) that is used to treat pain and inflammation in animals. It is a propionic acid derivative and is available in oral and injectable formulations. Carprofen is thought to work by inhibiting the production of prostaglandins, which are chemicals that cause pain and inflammation. It is studied extensively due to its effectiveness in managing pain in animals, particularly in cases of osteoarthritis and post-surgical pain. Carprofen is well-absorbed from the gastrointestinal tract and has a relatively long duration of action.'

carprofen: RN given refers to cpd without isomeric designation [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

carprofen : Propanoic acid in which one of the methylene hydrogens is substituted by a 6-chloro-9H-carbazol-2-yl group. A non-steroidal anti-inflammatory drug, it is no longer used in human medicine but is still used for treatment of arthritis in elderly dogs. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Cross-References

ID SourceID
PubMed CID2581
CHEMBL ID1316
CHEBI ID364453
SCHEMBL ID3909
MeSH IDM0049898

Synonyms (181)

Synonym
AC-1266
9h-carbazole-2-acetic acid, 6-chloro-.alpha.-methyl-, (.+-.)-
9h-carbazole-2-acetic acid, 6-chloro-.alpha.-methyl-, (-)-
2-(6-chloro-9h-carbazol-2-yl)propanoic acid
c-5720 ,
rimadyl
ro-20-5720
nsc 297935
carprofeno [inn-spanish]
9h-carbazole-2-acetic acid, 6-chloro-alpha-methyl-, (+-)-
carprofeno [spanish]
c 5720
carprofene [inn-french]
ccris 3507
einecs 258-712-4
6-chloro-alpha-methylcarbazole-2-acetic acid
brn 0487098
ro 20-5720
(+-)-6-chloro-alpha-methylcarbazole-2-acetic acid
carprofenum [inn-latin]
D03410
rimadyl (tn)
carprofen (usp/inn)
nsc297935
carprofen
53716-49-7
(.+-.)-6-chloro-.alpha.-methylcarbazole-2-acetic acid
9h-carbazole-2-acetic acid, (-)-
ro 20-5720/000
ridamyl
9h-carbazole-2-acetic acid, (.+-.)-
imadyl
nsc-297935
SPECTRUM5_001802
DB00821
6-chloro-alpha-methyl-9h-carbazole-2-acetic acid
(+/-)-6-chloro-alpha-methylcarbazole-2-acetic acid
(+/-)-2-(3-chloro-9h-carbazol-7-yl)propanoic acid
2-(6-chloro-9h-carbazol-2-yl)-propionic acid
NCGC00094937-02
NCGC00094937-01
KBIO3_001978
KBIOGR_001595
SPECTRUM3_000939
SPECTRUM4_001038
SPBIO_001112
SPECTRUM2_001236
SPECTRUM1502006
smr000718633
MLS001306441
HMS2092B16
MLS001201778
2-(6-chloro-9h-carbazol-2-yl)-propionic acid(carprofen)
bdbm50097346
ro-20-5720/000
carprofen for veterinary use
ro-205720000
CHEMBL1316 ,
HMS1921D04
carprofeno
carprofene
chebi:364453 ,
carprofenum
52263-47-5
STK711093
C18364
2-(6-chloranyl-9h-carbazol-2-yl)propanoic acid
A829748
BBL009935
nsc758154
pharmakon1600-01502006
nsc-758154
tox21_111363
dtxcid9025871
cas-53716-49-7
dtxsid1045871 ,
C2701
HMS2234P15
CCG-39146
AKOS005530663
(+-)-6-chlor-alpha-methyl-2-carbazolessigsaeure
carprofen [usan:usp:inn:ban]
unii-ffl0d546ho
carprodyl
carpaquin
5-22-03-00391 (beilstein handbook reference)
ffl0d546ho ,
norocarp
FT-0602833
gtpl7141
carprofen [who-dd]
carprofen [usan]
carprofen [green book]
carprofen for veterinary use [ep monograph]
carprofen [orange book]
(+/-)-6-chloro-.alpha.-methylcarbazole-2-acetic acid
carprofen [usp impurity]
carprofen [mart.]
carprofen [vandf]
carprofen [usp-rs]
carprofen [usp monograph]
9h-carbazole-2-acetic acid, 6-chloro-.alpha.-methyl, (+/-)-
carprofen [inn]
carprofen [mi]
SCHEMBL3909
NCGC00094937-04
tox21_111363_1
KS-1163
CS-4875
6-chloro-alpha-methyl-carbazole-2-acetic acid
9h-carbazole-2-acetic acid, 6-chloro-.alpha.-methyl-
HY-B1227
AB00876263_06
AB00876263_07
mfcd00079028
SR-01000837515-3
SR-01000837515-2
sr-01000837515
carprofen, vetranal(tm), analytical standard
carprofen, united states pharmacopeia (usp) reference standard
HMS3652E20
carprofen for system suitability, european pharmacopoeia (ep) reference standard
carprofen, european pharmacopoeia (ep) reference standard
carprofen, >=97% (hplc)
carprofen, pharmaceutical secondary standard; certified reference material
carprofen; (2rs)-2-(6-chloro-9h-carbazol-2-yl)propanoic acid
SBI-0052885.P002
NCGC00094937-05
HMS3715F09
SW199610-3
FT-0664393
FT-0664395
FT-0664394
(+/-)-6-chloro-alpha-methylcarbazole-2-aceticacid
S4136
Q905755
BRD-A17411484-001-05-1
HMS3885F07
HMS3748C07
D70911
rac carprofen
carprofen 1000 microg/ml in acetonitrile
(s)-alpha-methyl-6-chloro-9h-carbazole-2-acetic acid
EN300-120629
(r)-alpha-methyl-6-chloro-9h-carbazole-2-acetic acid
rimadylsterile
carprofene (inn-french)
carprieve
vetprofen
carprofen caplets, novox caplets
carprofen (usan:usp:inn:ban)
carprofenum (inn-latin)
levafen
carprofen (usp monograph)
carprofen flavored tablets
carprofen flavored
carprofen (usp impurity)
carprofen for veterinary use (ep monograph)
ostifen
truprofen flavored tab
quellin
carprieve injection
carprofen injection
carprofeno (inn-spanish)
movodyl
carprofen chewable tablets
(rs)-2-(6-chloro-9h-carbazol-2-yl)propanoic acid
rimadyl sterile injectable solution
carprofen (usp-rs)
carprofen sterile injectable solution
rimadyl chewable tablets
rimadyl caplets
rovera
carprieve chewable tablets
carprofen (mart.)
carprofen tablets
9h-carbazole-2-acetic acid, 6-chloro-alpha-methyl, (+/-)-
carprovet
rimadylcaplets
Z1530425063
SY052509

Research Excerpts

Overview

Carprofen (CPF) is a non-steroidal anti-inflammatory drug that has been widely used in livestock for the treatment of fever and inflammation. Carprofen was found to be a potent inhibitor of canine COX2.

ExcerptReferenceRelevance
"Carprofen (CPF) is a non-steroidal anti-inflammatory drug that has been widely used in livestock for the treatment of fever and inflammation. "( A dual-emissive supramolecular sensor for fast and ratiometric determination of carprofen in meat.
Chen, X; Chen, Z; Liu, B; Lv, T; Peng, X; Song, C; Wang, L; Zeng, C; Zhang, M; Zhang, S, 2023
)
2.58
"Carprofen was found to be a bactericidal drug that inhibited mycobacterial drug efflux mechanisms. "( Carprofen elicits pleiotropic mechanisms of bactericidal action with the potential to reverse antimicrobial drug resistance in tuberculosis.
Bhakta, S; Chapman, E; Chrzastek, A; Evangelopoulos, D; Hailes, HC; Hanrath, A; Lipman, M; Maitra, A; Martin, LT; McHugh, TD; Waddell, SJ, 2020
)
3.44
"Carprofen is a non-steroidal anti-inflammatory drug commonly used for pain control in dogs."( Interaction between maropitant and carprofen on sparing of the minimum alveolar concentration for blunting adrenergic response (MAC-BAR) of sevoflurane in dogs.
Fukui, S; Ishizuka, T; Itami, T; Miyoshi, K; Ooyama, N; Sano, T; Tamura, J; Umar, MA; Yamashita, K, 2017
)
1.45
"Carprofen is a potent photoallergen. "( Occupational carprofen photoallergic contact dermatitis.
Dawe, RS; Ferguson, J; Kerr, AC; Muller, F, 2008
)
2.16
"Carprofen is a nonsteroidal anti-inflammatory drug of the 2-arylpropionate subclass. "( Pharmacodynamics and enantioselective pharmacokinetics of racemic carprofen in the horse.
Landoni, MF; Lees, P, 2002
)
1.99
"Carprofen is a new non-steroidal anti-inflammatory drug and a phenylpropionic acid derivative. "( [Photosensitivity associated with carprofen (Imadyl), a new non-steroidal anti-inflammatory drug].
Harms, M; Merot, Y; Saurat, JH, 1983
)
1.99
"Carprofen is a new non-steroidal compound with analgesic, anti-inflammatory and anti-pyretic properties. "( Experience with carprofen in extra-articular inflammatory processes.
Gotter, G, 1982
)
2.05
"Carprofen is a new nonsteroidal antiinflammatory drug that is currently undergoing clinical trials in the United States."( Effects of indomethacin and carprofen on renal homeostasis in rheumatoid arthritis patients and in healthy individuals.
Benet, LZ; Furst, DE; Konikoff, JJ; Mandel, HG; Nicoll, D; Williams, RL,
)
1.15
"Carprofen is a propionic acid-derived NSAID that has anti-inflammatory, analgesic, and antipyretic activity."( Use of carprofen for the treatment of pain and inflammation in dogs.
Fox, SM; Johnston, SA, 1997
)
1.47
"Carprofen (1a) is a photosensitizing nonsteroidal anti-inflammatory drug. "( Photophysical and photochemical characterization of a photosensitizing drug: a combined steady state photolysis and laser flash photolysis study on carprofen.
Bosca, F; Encinas, S; Heelis, PF; Miranda, MA, 1997
)
1.94
"Carprofen was found to be a potent inhibitor of canine COX2. "( Evaluation of selective inhibition of canine cyclooxygenase 1 and 2 by carprofen and other nonsteroidal anti-inflammatory drugs.
Lundy, KM; Ricketts, AP; Seibel, SB, 1998
)
1.98
"Carprofen is a Non Steroidal Anti-Inflammatory Drug (NSAID) which is widely used for the treatment of musculoskeletal disorders in horses. "( Pharmacokinetics of carprofen enantiomers in equine plasma and synovial fluid - a comparison with ketoprofen.
Armstrong, S; Frean, S; Lake, A; Lees, P; Tricklebank, P, 1999
)
2.07
"Carprofen is a non-steroidal antiinflammatory drug with marked photosensitising properties. "( Photobinding of carprofen to protein.
Boscá, F; Castell, JV; Hye, A; Lovell, WW; Miranda, MA; Moser, J, 2000
)
2.1

Effects

Carprofen has a direct influence on chondrocyte activity, resulting in changes in rate of production of cartilage matrix. Carprofen and Celecoxib have been selected by the COVID Moonshot initiative for in vitro testing.

ExcerptReferenceRelevance
"Carprofen has a direct influence on chondrocyte activity, resulting in changes in rate of production of cartilage matrix."( Effect of carprofen on sulfated glycosaminoglycan metabolism, protein synthesis, and prostaglandin release by cultured osteoarthritic canine chondrocytes.
Benton, HP; Broderick-Villa, GA; Koolpe, M; Vasseur, PB, 1997
)
2.14
"Carprofen and Celecoxib have been selected by the COVID Moonshot initiative for in vitro testing; they show 3.97 and 11.90% M-pro inhibition at 50 µM, respectively."( Prediction of Novel Inhibitors of the Main Protease (M-pro) of SARS-CoV-2 through Consensus Docking and Drug Reposition.
Cereto-Massagué, A; Garcia-Vallvé, S; Gimeno, A; Macip, G; Mestres-Truyol, J; Ojeda-Montes, MJ; Pujadas, G; Saldivar-Espinoza, B, 2020
)
1.28
"Carprofen has a direct influence on chondrocyte activity, resulting in changes in rate of production of cartilage matrix."( Effect of carprofen on sulfated glycosaminoglycan metabolism, protein synthesis, and prostaglandin release by cultured osteoarthritic canine chondrocytes.
Benton, HP; Broderick-Villa, GA; Koolpe, M; Vasseur, PB, 1997
)
2.14

Actions

Carprofen did not cause clinically relevant adverse effects in dogs anesthetized for fracture repair after 5 days of treatment. Carprofen appears to produce less objective damage in the upper gastrointestinal tract than indomethacin at comparable clinical doses.

ExcerptReferenceRelevance
"Carprofen did not cause clinically relevant adverse effects in dogs anesthetized for fracture repair after 5 days of treatment, even when it was administered before surgery or given to patients with trauma-induced alterations in renal function or hemostasis."( Effects of preoperative administration of carprofen on renal function and hemostasis in dogs undergoing surgery for fracture repair.
Bergmann, HM; Kramer, S; Nolte, IJ, 2005
)
2.04
"(-)-Carprofen was found to inhibit the enzyme noncompetitively with respect to acetohexamide and competitively with respect to NADPH."( Stereoselective inhibition of carbonyl reductase from rabbit kidney by enantiomers of carprofen.
Higuchi, T; Imamura, Y; Otagiri, M, 1994
)
0.99
"Carprofen appears to produce less objective damage in the upper gastrointestinal tract than indomethacin at comparable clinical doses."( Effects of nonsteroidal, antiinflammatory drugs on gastrointestinal injury and prostanoid generation in healthy volunteers.
Enthoven, D; Levine, RA; Nandi, J; Petokas, S, 1988
)
1

Treatment

Carprofen and other NSAIDs can be used alongside FCA in rabbits to achieve desired levels of antibody production while minimizing pain and distress associated with the use of FCA. Carprofen-treated calves tended to be less sensitive ( = 0.097) to nociceptive threshold tests. Car profen did not significantly affect polyclonal antibody production.

ExcerptReferenceRelevance
"Carprofen treatment did not significantly affect polyclonal antibody production, which suggests that carprofen and other NSAIDs can be used alongside FCA in rabbits to achieve desired levels of antibody production while minimizing pain and distress associated with the use of FCA."( Antibody production in rabbits administered Freund's complete adjuvant and carprofen concurrently.
Bean, KD; Fishback, JE; Froude, JW; Green, CA; Stronsky, SM, 2016
)
1.39
"Carprofen-treated calves tended to be less sensitive ( = 0.097) to nociceptive threshold tests."( Impact of carprofen administration on stress and nociception responses of calves to cautery dehorning.
Barth, LA; Coetzee, JF; Gehring, R; Hsu, WH; Labeur, L; Millman, ST; Stock, ML; Van Engen, NK; Voris, EA; Wang, C; Wulf, LW, 2016
)
1.56
"Carprofen treatment induced phosphorylation of p38 MAPK as early as within 1 min."( Carprofen induction of p75NTR-dependent apoptosis via the p38 mitogen-activated protein kinase pathway in prostate cancer cells.
Djakiew, D; Khwaja, FS; Pattabiraman, N; Quann, EJ; Wynne, S, 2008
)
2.51
"Carprofen treatment resulted in an earlier normalization of the clinical severity score."( Effect of carprofen treatment following experimentally induced Escherichia coli mastitis in primiparous cows.
Boutet, P; Burvenich, C; Duchateau, L; Lekeux, P; Paape, MJ; Rainard, P; Vangroenweghe, F, 2005
)
1.45
"Carprofen treatment had no effect on platelet aggregation while ketoprofen decreased the aggregation maximum."( Influencing factors of ADP-induced, epinephrine-induced and ristomycin-induced platelet aggregation in dogs.
Gaál, T; Halmay, D; Kocsis, R, 2008
)
1.07
"Carprofen treatment decreased the width of osteophytes (p < 0.01), the size of cartilage lesions, and the histologic severity of cartilage lesions (p < 0.008). "( Carprofen simultaneously reduces progression of morphological changes in cartilage and subchondral bone in experimental dog osteoarthritis.
Fernandes, JC; Hilal, G; Jolicoeur, FC; Jovanovic, DV; Lajeunesse, D; Lascau-Coman, V; Martel-Pelletier, J; Pelletier, JP, 2000
)
3.19
"Carprofen treatment also delays and/or prevents the abnormal metabolism of subchondral osteoblasts in this model."( Carprofen simultaneously reduces progression of morphological changes in cartilage and subchondral bone in experimental dog osteoarthritis.
Fernandes, JC; Hilal, G; Jolicoeur, FC; Jovanovic, DV; Lajeunesse, D; Lascau-Coman, V; Martel-Pelletier, J; Pelletier, JP, 2000
)
2.47
"Treatment with carprofen at ET had no significant effects on plasma P₄ concentrations and rate of embryo mortality."( Evaluation of treatments with hCG and carprofen at embryo transfer in a demi-embryo and recipient virgin heifer model.
Chagas E Silva, J; Diniz, P; Lopes-da-Costa, L; Torres, A, 2013
)
1
"Treatment with carprofen or DNP increased the mannitol flux, but pretreatment with tempol mitigated the carprofen effect."( Carprofen-induced oxidative stress in mitochondria of the colonic mucosa of the dog.
Davidson, JR; Hartmann, E; Hosgood, G; McConnico, RS; Morgan, TW; Snow, LA, 2014
)
2.18
"Treatment with carprofen alone caused a slight but nonsignificant improvement in weight-bearing load on the arthritic limb, compared with the control treatment."( Analgesic effects of carprofen and liposome-encapsulated butorphanol tartrate in Hispaniolan parrots (Amazona ventralis) with experimentally induced arthritis.
Brown, CS; Heath, TD; Keuler, NS; Klauer, JM; Krugner-Higby, LA; Paul-Murphy, JR; Sladky, KK; Stading, BR, 2009
)
1.01
"Treatment with carprofen is consistently associated with better functional outcome."( The anti-inflammatory drug carprofen improves long-term outcome and induces gliogenesis after traumatic brain injury.
Alexandrovich, AG; Leker, RR; Shohami, E; Thau-Zuchman, O; Trembovler, V, 2012
)
1.02
"Treatment with carprofen (P ≤ 0.01) and tramadol (P ≤ 0.001) led to improved mobility assessed by owner questionnaire."( Effect of analgesic therapy on clinical outcome measures in a randomized controlled trial using client-owned dogs with hip osteoarthritis.
Bleedorn, JA; Cozzi, EM; Holzman, G; Jacobson, PB; Malek, S; Muir, P; Nemke, B; Sample, SJ; Schaefer, SL; Schwartz, Z, 2012
)
0.72
"Treatment with carprofen decreased clot strength and platelet aggregation."( Changes in platelet function, hemostasis, and prostaglandin expression after treatment with nonsteroidal anti-inflammatory drugs with various cyclooxygenase selectivities in dogs.
Brainard, BM; Budsberg, SC; Callan, MB; Driessen, B; Meredith, CP; Otto, CM; Shofer, FS, 2007
)
0.68
"Dogs treated with carprofen showed a marked decrease in the remodeling activity with normal plate thickness, and subchondral bone morphology resembling that of normal dogs."( Carprofen simultaneously reduces progression of morphological changes in cartilage and subchondral bone in experimental dog osteoarthritis.
Fernandes, JC; Hilal, G; Jolicoeur, FC; Jovanovic, DV; Lajeunesse, D; Lascau-Coman, V; Martel-Pelletier, J; Pelletier, JP, 2000
)
2.07

Toxicity

Carprofen at 20 mg/kg appears to have minimal toxic effects with regard to the parameters measured. Vultures exposed to carprofen as residues in the kidney tissue or pure drug equivalents showed no toxic signs.

ExcerptReferenceRelevance
" The two most obvious potential advantages of carprofen are that it seems to have a low profile of major gastrointestinal adverse reactions (it may cause minor complaints similar to those seen with indomethacin, but thus far has caused no documented gastric or duodenal ulcers at 300 mg/d); and that, like naproxen, it offers the convenience of twice-a-day dosing."( Carprofen: a new nonsteroidal antiinflammatory drug. Pharmacology, clinical efficacy and adverse effects.
Bagby, GF; O'Brien, WM,
)
1.83
"Suspected adverse reactions (SARs) reported for Cartrophen Vet (100 mg sodium pentosan polysulphate/ml) to the Veterinary Medicines Directorate in the UK for the period January 1991 to October 1999 were reviewed."( Safety of Cartrophen Vet in the dog: review of adverse reaction reports in the UK.
Cawdery, MJ; Cullis-Hill, D; Ghosh, P; Hannon, RL; Smith, JG, 2003
)
0.32
"To evaluate the adverse effects of carprofen in dogs after oral administration for 2 months."( Evaluation of adverse effects of long-term orally administered carprofen in dogs.
Hielm-Björkman, AK; Kejonen, J; Raekallio, MR; Salonen, HM; Sankari, SM, 2006
)
0.85
" Dogs were observed by owners for adverse effects."( Evaluation of adverse effects of long-term orally administered carprofen in dogs.
Hielm-Björkman, AK; Kejonen, J; Raekallio, MR; Salonen, HM; Sankari, SM, 2006
)
0.57
"To evaluate adverse effects of long-term oral administration of carprofen, etodolac, flunixin meglumine, ketoprofen, and meloxicam in dogs."( Evaluation of adverse effects of long-term oral administration of carprofen, etodolac, flunixin meglumine, ketoprofen, and meloxicam in dogs.
Basílio, AC; Brandão, CV; Luna, SP; Machado, LP; Moutinho, FQ; Steagall, PV; Takahira, RK, 2007
)
0.82
"Carprofen induced the lowest frequency of gastrointestinal adverse effects, followed by meloxicam."( Evaluation of adverse effects of long-term oral administration of carprofen, etodolac, flunixin meglumine, ketoprofen, and meloxicam in dogs.
Basílio, AC; Brandão, CV; Luna, SP; Machado, LP; Moutinho, FQ; Steagall, PV; Takahira, RK, 2007
)
2.02
" We recommend KXA as a safe and reliable anesthetic for mice requiring a surgical plane of anesthesia."( Safety and efficacy of various combinations of injectable anesthetics in BALB/c mice.
Belicha-Villanueva, A; Buitrago, S; Martin, TE; Tetens-Woodring, J; Wilding, GE, 2008
)
0.35
"This study evaluated the adverse effects of carprofen in seven healthy cats."( Evaluation of the adverse effects of subcutaneous carprofen over six days in healthy cats.
Mantovani, FB; Moutinho, FQ; Passarelli, D; Steagall, PV; Thomassian, A, 2009
)
0.87
" The treatments had a similar safety profile as evidenced by documented adverse events and summaries of clinical pathology parameters."( Comparative efficacy and safety of mavacoxib and carprofen in the treatment of canine osteoarthritis.
Becskei, C; Chaudhry, Y; Payne-Johnson, M; Stegemann, MR, 2015
)
0.67
"The following study evaluates the overt toxic potential of carprofen (CRP), flunixin (FXN) and phenylbutazone (PBZ) in Old world vultures in relation to historic toxicity data for diclofenac and ketoprofen, with the Cape vulture (Gyps coprotheres) being the indicator species."( The Safety and Pharmacokinetics of Carprofen, Flunixin and Phenylbutazone in the Cape Vulture (Gyps coprotheres) following Oral Exposure.
Cromarty, D; Duncan, N; Fourie, T; Naidoo, V; Wolter, K, 2015
)
0.94
" Vultures exposed to carprofen as residues in the kidney tissue or pure drug equivalents showed no toxic signs."( The use of toxicokinetics and exposure studies to show that carprofen in cattle tissue could lead to secondary toxicity and death in wild vultures.
Chipangura, J; Duncan, N; Galligan, TH; Green, RE; Naidoo, V; Taggart, MA; Wolter, K, 2018
)
1.04
" Both meloxicam and diclofenac exerted toxic effects on the hepatic cells."( The use of liver slices from the Cape vulture (Gyps coprotheres) to better understand the role of liver toxicity of non-steroidal anti-inflammatory drugs (NSAIDs) in vultures.
Adawaren, EO; Bekker, L; Duncan, N; Mukandiwa, L; Naidoo, V; Njoya, EM, 2018
)
0.48
" These findings suggest that 20 mg/kg of meloxicam in mice causes gastric toxicity when given for 3 or 7 d and should be used cautiously; however, carprofen at 20 mg/kg appears to have minimal toxic effects with regard to the parameters measured."( Toxic Effects of High-dose Meloxicam and Carprofen on Female CD1 Mice.
Bailey, AL; Kendall, LV; McGee, W; Singh, B, 2022
)
1.19

Pharmacokinetics

A tissue cage model of inflammation in calves was used to determine the pharmacokinetic and pharmacodynamic properties of individual carprofen enantiomers. Carprofen concentration data were natural log transformed and geometric means were calculated for maximum plasma concentration (Cmax) and area under the plasma concentration-time curve (AUC0--12)

ExcerptReferenceRelevance
"4 ml kg-1), a prolonged elimination half-life (t1/2 beta, 26."( Pharmacokinetics of carprofen administered intravenously to sheep.
Baxter, P; Nolan, AM; Welsh, EM, 1992
)
0.61
" The pharmacokinetic characteristics of carprofen in healthy cows were a small volume of distribution (0."( Pharmacodynamics and pharmacokinetics of carprofen, a non-steroidal anti-inflammatory drug, in healthy cows and cows with Escherichia coli endotoxin-induced mastitis.
Brand, A; Heizmann, P; Lohuis, JA; Ludwig, B; Rehm, WF; Rohde, E; van Miert, AS; van Werven, T, 1991
)
0.81
"In this overview the pharmacokinetic behaviour of carprofen in healthy subjects is described."( Pharmacokinetic properties of carprofen in humans.
Crevoisier, C, 1982
)
0.81
" Both enantiomers distributed into peripheral subcutaneous tissue cage fluids, but Cmax and AUC values were lower for both transudate (non-stimulated tissue cage fluid) and exudate (induced by the intracaveal administration of the irritant carrageenan) than for plasma."( Stereospecific pharmacodynamics and pharmacokinetics of carprofen in the dog.
Delatour, P; Lees, P; McKellar, QA, 1994
)
0.53
"7 mg racemic carprofen/kg bwt, mean values for pharmacokinetic parameters were 18."( Pharmacodynamics and pharmacokinetics of carprofen in the horse.
Lees, P; Ludwig, B; May, SA; McKellar, Q, 1994
)
0.92
") dose, and computer modelling to determine the pharmacokinetic parameters of the enantiomers in these two body fluids."( Pharmacokinetics of carprofen enantiomers in equine plasma and synovial fluid - a comparison with ketoprofen.
Armstrong, S; Frean, S; Lake, A; Lees, P; Tricklebank, P, 1999
)
0.63
" Early and extended sample time points suggest that the pharmacokinetics of carprofen in the cat fit a 2-compartment model, with a long elimination half-life (t1/2) of 20."( The pharmacokinetics and effects of intravenously administered carprofen and salicylate on gastrointestinal mucosa and selected biochemical measurements in healthy cats.
Balmer, TV; Boyle, J; MacHon, R; Parton, K; Whittem, T, 2000
)
0.78
" There were no significant differences between the mean pharmacokinetic parameters measured on the three occasions, suggesting that carprofen was not accumulated and that tolerance to the drug did not develop."( Clinical efficacy and pharmacokinetics of carprofen in the treatment of dogs with osteoarthritis.
AliAbadi, FS; Lees, P; Lipscomb, VJ; Muir, P; Pead, MJ, 2002
)
0.78
" Carprofen concentration data were natural log transformed and geometric means were calculated for maximum plasma concentration (Cmax) and area under the plasma concentration-time curve (AUC0--12) following the first dose and Cmax and AUC0--12 following administration of the last dose."( The steady-state pharmacokinetics and bioequivalence of carprofen administered orally and subcutaneously in dogs.
Boy, MG; Chieffo, C; Clark, TP; Huhn, JC; Nimz, EL; Wang, C, 2003
)
1.48
" A plasma concentrationtime curve for each donkey and horse was analyzed separately to estimate noncompartmental pharmacokinetic variables."( Pharmacokinetics of R(-) and S(+) carprofen after administration of racemic carprofen in donkeys and horses.
Bennett, BS; Burchfield, ML; Matthews, NS; Mealey, KL; Peck, KE; Taylor, TS, 2004
)
0.6
" The elimination half-life remained constant."( Effects of urine alkalization and activated charcoal on the pharmacokinetics of orally administered carprofen in dogs.
Honkavaara, JM; Peltoniemi, SM; Raekallio, MR; Säkkinen, MS, 2007
)
0.56
" The development of NSAIDs having safer therapeutic profile depends on the better understanding of their mechanisms, physicochemical and pharmacokinetic properties."( Self-organizing molecular field analysis of NSAIDs: assessment of pharmacokinetic and physicochemical properties using 3D-QSPkR approach.
Kumar, M; Sinha, VR; Thareja, S, 2012
)
0.38
" However, using in vitro susceptibility in CAMHB and in vivo-determined pharmacokinetic (PK) variables, average and minimum oxytetracycline concentrations relative to MIC (C(av)/MIC and C(min)/MIC) predicted achievement of efficacy for approximately 48 hours after dosing."( Pharmacodynamics of oxytetracycline administered alone and in combination with carprofen in calves.
Brentnall, C; Cheng, Z; Lees, P; McKellar, QA, 2012
)
0.61
"A tissue cage model of inflammation in calves was used to determine the pharmacokinetic and pharmacodynamic properties of individual carprofen enantiomers, following the administration of the racemate."( Influence of oxytetracycline on carprofen pharmacodynamics and pharmacokinetics in calves.
Brentnall, C; Cheng, Z; Lees, P; McKellar, QA, 2013
)
0.88
"The pharmacokinetic (PK) and pharmacodynamic (PD) profiles of oxytetracycline were investigated, when administered both alone and in the presence of carprofen, in healthy calves."( Pharmacokinetic-pharmacodynamic integration and modelling of oxytetracycline administered alone and in combination with carprofen in calves.
Brentnall, C; Cheng, Z; Lees, P; McKellar, QA, 2013
)
0.8
" The objective of this study was to determine the unbound concentration of carprofen in canine interstitial fluid (ISF) using in vivo ultrafiltration and to compare pharmacokinetic parameters of free carprofen concentrations between inflamed and control tissue sites."( Carprofen pharmacokinetics in plasma and in control and inflamed canine tissue fluid using in vivo ultrafiltration.
Messenger, KM; Papich, MG; Wofford, JA, 2016
)
2.11
"2 hours (Tmax) respectively and a half-life of elimination of 13."( The Safety and Pharmacokinetics of Carprofen, Flunixin and Phenylbutazone in the Cape Vulture (Gyps coprotheres) following Oral Exposure.
Cromarty, D; Duncan, N; Fourie, T; Naidoo, V; Wolter, K, 2015
)
0.69
" Pharmacokinetic studies on groups of six greyhounds were performed to measure plasma and urine levels of carprofen and firocoxib to inform medication control advice."( Pharmacokinetics of carprofen and firocoxib for medication control in racing greyhounds.
Colgan, SA; Karamatic, SL; Li, EC; Morris, TH; Paine, SW; Zahra, PW, 2020
)
1.1
" A pharmacokinetic study in rabbits has been performed to evaluate carprofen nanoparticles after intraarticular administration."( In vivo pharmacokinetic evaluation of carprofen delivery from intra-articular nanoparticles in rabbits: A population modelling approach.
Boix-Montañés, A; Calpena-Campmany, AC; Colom, H; Parra-Coca, A, 2021
)
1.13

Compound-Compound Interactions

There were no clinically relevant differences in the PK profile of oxytetracycline when administered alone and when administered with carprofen. The aim of this study was to evaluate the analgesic efficacy of carProfen in combination with one of two commercial formulations of buprenorphine.

ExcerptReferenceRelevance
" There were no clinically relevant differences in the PK profile of oxytetracycline when administered alone and when administered with carprofen."( Pharmacokinetic-pharmacodynamic integration and modelling of oxytetracycline administered alone and in combination with carprofen in calves.
Brentnall, C; Cheng, Z; Lees, P; McKellar, QA, 2013
)
0.8
" In explant culture, low MW HA combined with 12."( Effects of low molecular weight hyaluronan combined with carprofen on canine osteoarthritis articular chondrocytes and cartilage explants in vitro.
Buddhachat, K; Chomdej, S; Euppayo, T; Harada, Y; Nganvongpanit, K; Ongchai, S; Pradit, W; Siengdee, P; Viriyakhasem, N, 2015
)
0.66

Bioavailability

Carprofen was well absorbed after administration and reached concentrations that inhibited ex vivo PGE concentrations for 72 h (subcutaneous) and 96 h (oral) compared with placebo-treated calves. The main features of carprofen pharmacokinetics were a low distribution volume, a relatively long elimination half-life and the predominance of the R(-) enantiomer.

ExcerptReferenceRelevance
" After rectal administration, the rate of absorption evaluated through tmax and calculation of mean absorption times was always slower than after oral dosing."( Biopharmaceutical evaluation of carprofen following single intravenous, oral, and rectal doses in dogs.
Guentert, TW; Schmitt, M, 1990
)
0.56
" The maximum concentration in plasma is reached after 1 hour and the absolute bioavailability of the oral forms reaches values of over 90%."( Pharmacokinetic properties of carprofen in humans.
Crevoisier, C, 1982
)
0.55
" Each of the enantiomers achieved similar plasma bioavailability following administration as the racemate as they did following their separate administration."( Stereospecific pharmacodynamics and pharmacokinetics of carprofen in the dog.
Delatour, P; Lees, P; McKellar, QA, 1994
)
0.53
" ML-1,785,713 has oral bioavailability and low systemic clearance that is comparable to other non-steroidal anti-inflammatory drugs."( In vitro effects and in vivo efficacy of a novel cyclooxygenase-2 inhibitor in dogs with experimentally induced synovitis.
Andersen, DR; Black, WC; Brideau, C; Hanson, PD; Hickey, GJ; McCann, ME; Zhang, D, 2004
)
0.32
" bioavailability [F (%)] for both R(-)- and S(+)-CPF was high, 94."( Enantioselective pharmacokinetics of racemic carprofen in New Zealand white rabbits.
Craigmill, AL; Hawkins, MG; Taylor, IT; Tell, LA, 2008
)
0.61
"To determine the efficacy and bioavailability of non-steroidal anti-inflammatory drugs (NSAIDs) when administered orally to sheep."( Randomised trial of the bioavailability and efficacy of orally administered flunixin, carprofen and ketoprofen in a pain model in sheep.
Colditz, IG; Hinch, G; Lee, C; Marini, D; Petherick, JC; Pippia, J, 2015
)
0.64
"The ATP-binding cassette transporter P-glycoprotein (P-gp) is known to limit both brain penetration and oral bioavailability of many chemotherapy drugs."( A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
Ambudkar, SV; Brimacombe, KR; Chen, L; Gottesman, MM; Guha, R; Hall, MD; Klumpp-Thomas, C; Lee, OW; Lee, TD; Lusvarghi, S; Robey, RW; Shen, M; Tebase, BG, 2019
)
0.51

Dosage Studied

Carprofen appears to be well tolerated, and at the dosage used its efficacy was good and equal to that of indomethacin. Results have suggested that the dosing intervals for carprofen that are used in horses may not be appropriate for use in donkeys.

ExcerptRelevanceReference
" No significant difference in rates of absorption of carprofen from rectal solution and suppository was seen; this allowed the conclusion that drug release from the semi-solid dosage form was not the rate-limiting step in carprofen absorption from the suppository."( Biopharmaceutical evaluation of carprofen following single intravenous, oral, and rectal doses in dogs.
Guentert, TW; Schmitt, M, 1990
)
0.81
" However, there was no strong dose-response relation."( [Modulation of the oxidative metabolism of granulocytes by nonsteroidal anti-inflammatory agents].
Kapp, A; Schöpf, E, 1987
)
0.27
" The dosing range used (0."( Renal clearance of carprofen in the isolated perfused rat kidney.
Bekersky, I; Colburn, WA,
)
0.46
"A high-performance liquid chromatographic method for the analysis of carprofen in solid dosage forms and as the bulk drug substance was developed."( Analysis of carprofen dosage forms and drug substance by high-performance liquid chromatography.
Casey, DL; Del Mauro, MD; Ross, AJ; Sokoloff, HK, 1984
)
0.88
" Each subject was examined in basal conditions and after dosing with carprofen and ASA in random sequence with a 10-day washout period between tests."( Antiinflammatory drugs and gastric emptying. A comparison between acetylsalicylic acid and carprofen.
Calbiani, B; Cisternino, M; Colombi-Zinelli, L; Papa, N; Rinetti, M; Ugolotti, G, 1982
)
0.72
" For most of the efficacy variables studied, the carprofen high dosage regimen at weeks 5 and 6 was shown statistically superior or at least not different from the indomethacin group; both of these were superior to the carprofen low dosage regimen."( Comparative evaluation of carprofen and indomethacin in rheumatoid patients.
Caron, M; Lussier, A; Rouleau, L; Tétreault, L, 1980
)
0.82
" In general carprofen appears to be well tolerated, and at the dosage used its efficacy was good and equal to that of indomethacin."( Carprofen in soft-tissue rheumatism. A controlled trial.
Schorn, D, 1981
)
2.08
" However at a lower dosage (7."( Action of a new non-steroid anti-inflammatory drug, carprofen (Ro 20-5720) on activation of the complement system: an in vitro research.
Auteria, A; Di Perri, T; Laghi Pasini, F, 1982
)
0.51
" Further dosing with the particular analgesic was allowed if a cat was exhibiting unacceptable pain."( Comparison of carprofen and pethidine as postoperative analgesics in the cat.
Balmer, TV; Irvine, D; Jones, RS; Roberts, MJ; Slingsby, L; Taylor, PM; Waterman, AE; Waters, C, 1998
)
0.66
" Dose-response curves were plotted, and calculations were performed to identify concentrations that caused 50% inhibition (IC50 [microM]) for each isozyme."( Evaluation of selective inhibition of canine cyclooxygenase 1 and 2 by carprofen and other nonsteroidal anti-inflammatory drugs.
Lundy, KM; Ricketts, AP; Seibel, SB, 1998
)
0.53
" The COX selectivity of each drug was evaluated from dose-response curves by calculating a ratio (COX-1:COX-2) of inhibitory concentration values on the basis of concentrations that reduced PGE2 by 50% in each COX model."( In vitro effects of nonsteroidal anti-inflammatory drugs on cyclooxygenase activity in dogs.
Benn, SJ; Conlon, P; Kay-Mugford, P; LaMarre, J, 2000
)
0.31
" Oral dosing of placebo, carprofen, or deracoxib was done 30 minutes before intraarticular injection of urate crystal suspension for induction of synovitis."( Effect of deracoxib, a new COX-2 inhibitor, on the prevention of lameness induced by chemical synovitis in dogs.
Buonomo, FC; Millis, DL; Moyers, T; Weigel, JP, 2002
)
0.62
"Results have suggested that the dosing intervals for carprofen that are used in horses may not be appropriate for use in donkeys."( Pharmacokinetics of R(-) and S(+) carprofen after administration of racemic carprofen in donkeys and horses.
Bennett, BS; Burchfield, ML; Matthews, NS; Mealey, KL; Peck, KE; Taylor, TS, 2004
)
0.85
"To determine the effects of feeding a diet supplemented with fish oil omega-3 fatty acids on carprofen dosage in dogs with osteoarthritis."( A multicenter study of the effect of dietary supplementation with fish oil omega-3 fatty acids on carprofen dosage in dogs with osteoarthritis.
Allen, TA; Brejda, J; Dodd, CE; Fritsch, DA; Hahn, KA; Jewell, DE; Leventhal, PS; Sixby, KA, 2010
)
0.8
"Linear regression analysis indicated that over the 12-week study period, carprofen dosage decreased significantly faster among dogs fed the supplemented diet than among dogs fed the control diet."( A multicenter study of the effect of dietary supplementation with fish oil omega-3 fatty acids on carprofen dosage in dogs with osteoarthritis.
Allen, TA; Brejda, J; Dodd, CE; Fritsch, DA; Hahn, KA; Jewell, DE; Leventhal, PS; Sixby, KA, 2010
)
0.81
" Neither flunixin meglumine nor carprofen improved conception rates to first service in dairy cattle in the dosage and administration schedule tested."( Effect of flunixin meglumine and carprofen on pregnancy rates in dairy cattle.
Heuwieser, W; von Krueger, X, 2010
)
0.93
" In addition, we compiled dose-response data for 4 commonly used analgesics: buprenorphine, carprofen, ketoprofen, and acetaminophen."( Using the Mouse Grimace Scale to reevaluate the efficacy of postoperative analgesics in laboratory mice.
King, OD; Matsumiya, LC; Mogil, JS; Sorge, RE; Sotocinal, SG; Tabaka, JM; Wieskopf, JS; Zaloum, A, 2012
)
0.6
" These data provide a basis for the rational use of carprofen with oxytetracycline in calves and indicate that no alteration to carprofen dosage is required when the drugs are co-administered."( Influence of oxytetracycline on carprofen pharmacodynamics and pharmacokinetics in calves.
Brentnall, C; Cheng, Z; Lees, P; McKellar, QA, 2013
)
0.92
" It has a long plasma half-life, requiring less frequent dosing and supporting increased owner compliance in treating their dogs."( The long-acting COX-2 inhibitor mavacoxib (Trocoxil™) has anti-proliferative and pro-apoptotic effects on canine cancer cell lines and cancer stem cells in vitro.
Argyle, DJ; Argyle, SA; Kamida, A; Morrison, KO; Pang, LY, 2014
)
0.4
" Sustained-release (SR) formulations of analgesics maintain plasma levels that should be sufficient to provide sustained analgesia yet require less frequent dosing and thus less handling of and stress to the animals."( Pharmacokinetics of sustained-release analgesics in mice.
Dorsey, K; Gustafson, DL; Hansen, RJ; Kang, S; Kendall, LV; Lunghofer, PJ, 2014
)
0.4
" Of 139 dogs screened, 124 were suitable for study participation: 62 of which were dosed with mavacoxib and 62 with carprofen."( Comparative efficacy and safety of mavacoxib and carprofen in the treatment of canine osteoarthritis.
Becskei, C; Chaudhry, Y; Payne-Johnson, M; Stegemann, MR, 2015
)
0.88
" Overall, at the dosing regimen studied, the effect of carprofen on sensitivity and stress following cautery dehorning was minimal."( Impact of carprofen administration on stress and nociception responses of calves to cautery dehorning.
Barth, LA; Coetzee, JF; Gehring, R; Hsu, WH; Labeur, L; Millman, ST; Stock, ML; Van Engen, NK; Voris, EA; Wang, C; Wulf, LW, 2016
)
1.08
"Postoperative analgesia in laboratory rats is complicated by the frequent handling associated with common analgesic dosing requirements."( Postoperative Analgesia Due to Sustained-Release Buprenorphine, Sustained-Release Meloxicam, and Carprofen Gel in a Model of Incisional Pain in Rats (Rattus norvegicus).
Adams, SC; Felt, SA; Jampachaisri, K; Pacharinsak, C; Seymour, TL; Yeomans, DC, 2016
)
0.65
"61 h from healthy birds dosed intravenously at 5 mg/kg."( The use of toxicokinetics and exposure studies to show that carprofen in cattle tissue could lead to secondary toxicity and death in wild vultures.
Chipangura, J; Duncan, N; Galligan, TH; Green, RE; Naidoo, V; Taggart, MA; Wolter, K, 2018
)
0.72
" When administered to laboratory rodents, small volumes of the stock solution are diluted to provide accurate dosing and ease of administration."( Strength and Sterility of Stock and Diluted Carprofen Over Time.
Lester, PA; Renner, DM; Xu, JJ, 2021
)
0.88
" Pain and inflammation were assessed by masked investigators via mechanical nociceptive threshold testing and the short form of the Glasgow Composite Pain Scale before drug administration and at multiple time points for 72 hours following dosing and surgery."( Preliminary evaluation of the effects of grapiprant compared with carprofen on acute pain and inflammation following ovariohysterectomy in dogs.
Barnes, DN; Enomoto, H; Long, SM; Messenger, KM; Southern, BL, 2022
)
0.96
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Roles (3)

RoleDescription
non-steroidal anti-inflammatory drugAn anti-inflammatory drug that is not a steroid. In addition to anti-inflammatory actions, non-steroidal anti-inflammatory drugs have analgesic, antipyretic, and platelet-inhibitory actions. They act by blocking the synthesis of prostaglandins by inhibiting cyclooxygenase, which converts arachidonic acid to cyclic endoperoxides, precursors of prostaglandins.
EC 1.14.99.1 (prostaglandin-endoperoxide synthase) inhibitorA compound or agent that combines with cyclooxygenases (EC 1.14.99.1) and thereby prevents its substrate-enzyme combination with arachidonic acid and the formation of icosanoids, prostaglandins, and thromboxanes.
photosensitizing agentA chemical compound that can be excited by light of a specific wavelength and subsequently transfer energy to a chosen reactant. This is commonly molecular oxygen within a cancer tissue, which is converted to (highly rective) singlet state oxygen. This rapidly reacts with any nearby biomolecules, ultimately killing the cancer cells.
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (2)

ClassDescription
carbazoles
organochlorine compoundAn organochlorine compound is a compound containing at least one carbon-chlorine bond.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Pathways (1)

PathwayProteinsCompounds
Carprofen Action Pathway2967

Protein Targets (31)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Chain A, Beta-lactamaseEscherichia coli K-12Potency15.84890.044717.8581100.0000AID485294
LuciferasePhotinus pyralis (common eastern firefly)Potency33.55860.007215.758889.3584AID1224835; AID588342; AID624030
RAR-related orphan receptor gammaMus musculus (house mouse)Potency33.49150.006038.004119,952.5996AID1159521
SMAD family member 2Homo sapiens (human)Potency16.93010.173734.304761.8120AID1346859
SMAD family member 3Homo sapiens (human)Potency16.93010.173734.304761.8120AID1346859
Microtubule-associated protein tauHomo sapiens (human)Potency35.48130.180013.557439.8107AID1460
progesterone receptorHomo sapiens (human)Potency13.33320.000417.946075.1148AID1346784
nonstructural protein 1Influenza A virus (A/WSN/1933(H1N1))Potency11.22020.28189.721235.4813AID2326
retinoic acid nuclear receptor alpha variant 1Homo sapiens (human)Potency26.60320.003041.611522,387.1992AID1159555
retinoid X nuclear receptor alphaHomo sapiens (human)Potency4.25270.000817.505159.3239AID1159527
estrogen nuclear receptor alphaHomo sapiens (human)Potency7.56240.000229.305416,493.5996AID743075
67.9K proteinVaccinia virusPotency5.01190.00018.4406100.0000AID720580
peroxisome proliferator-activated receptor deltaHomo sapiens (human)Potency10.45710.001024.504861.6448AID743212; AID743215
peroxisome proliferator activated receptor gammaHomo sapiens (human)Potency26.60110.001019.414170.9645AID743191
vitamin D (1,25- dihydroxyvitamin D3) receptorHomo sapiens (human)Potency9.43840.023723.228263.5986AID743222
activating transcription factor 6Homo sapiens (human)Potency0.06740.143427.612159.8106AID1159516
vitamin D3 receptor isoform VDRAHomo sapiens (human)Potency89.12510.354828.065989.1251AID504847
histone deacetylase 9 isoform 3Homo sapiens (human)Potency30.04740.037617.082361.1927AID1259364; AID1259388
gemininHomo sapiens (human)Potency1.25890.004611.374133.4983AID624297
histone acetyltransferase KAT2A isoform 1Homo sapiens (human)Potency31.62280.251215.843239.8107AID504327
Cellular tumor antigen p53Homo sapiens (human)Potency33.49150.002319.595674.0614AID651631
TAR DNA-binding protein 43Homo sapiens (human)Potency2.51191.778316.208135.4813AID652104
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
ATP-binding cassette sub-family C member 3Homo sapiens (human)IC50 (µMol)133.00000.63154.45319.3000AID1473740
Multidrug resistance-associated protein 4Homo sapiens (human)IC50 (µMol)3.00000.20005.677410.0000AID1473741
Bile salt export pumpHomo sapiens (human)IC50 (µMol)133.00000.11007.190310.0000AID1473738
Prostaglandin G/H synthase 1Ovis aries (sheep)IC50 (µMol)16.16670.00032.177410.0000AID492859; AID614601; AID701504
Prostaglandin G/H synthase 1Homo sapiens (human)IC50 (µMol)13.20000.00021.557410.0000AID220490
Prostaglandin G/H synthase 2Homo sapiens (human)IC50 (µMol)1.05100.00010.995010.0000AID220491; AID492858; AID614602; AID701505
Fatty-acid amide hydrolase 1Rattus norvegicus (Norway rat)IC50 (µMol)27.15000.00051.33138.0000AID1507766; AID701504
Canalicular multispecific organic anion transporter 1Homo sapiens (human)IC50 (µMol)133.00002.41006.343310.0000AID1473739
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Activation Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Complement C5Homo sapiens (human)Kd0.58000.57000.62500.7100AID1601161
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (244)

Processvia Protein(s)Taxonomy
xenobiotic metabolic processATP-binding cassette sub-family C member 3Homo sapiens (human)
xenobiotic transmembrane transportATP-binding cassette sub-family C member 3Homo sapiens (human)
bile acid and bile salt transportATP-binding cassette sub-family C member 3Homo sapiens (human)
glucuronoside transportATP-binding cassette sub-family C member 3Homo sapiens (human)
xenobiotic transportATP-binding cassette sub-family C member 3Homo sapiens (human)
transmembrane transportATP-binding cassette sub-family C member 3Homo sapiens (human)
leukotriene transportATP-binding cassette sub-family C member 3Homo sapiens (human)
monoatomic anion transmembrane transportATP-binding cassette sub-family C member 3Homo sapiens (human)
transport across blood-brain barrierATP-binding cassette sub-family C member 3Homo sapiens (human)
prostaglandin secretionMultidrug resistance-associated protein 4Homo sapiens (human)
cilium assemblyMultidrug resistance-associated protein 4Homo sapiens (human)
platelet degranulationMultidrug resistance-associated protein 4Homo sapiens (human)
xenobiotic metabolic processMultidrug resistance-associated protein 4Homo sapiens (human)
xenobiotic transmembrane transportMultidrug resistance-associated protein 4Homo sapiens (human)
bile acid and bile salt transportMultidrug resistance-associated protein 4Homo sapiens (human)
prostaglandin transportMultidrug resistance-associated protein 4Homo sapiens (human)
urate transportMultidrug resistance-associated protein 4Homo sapiens (human)
glutathione transmembrane transportMultidrug resistance-associated protein 4Homo sapiens (human)
transmembrane transportMultidrug resistance-associated protein 4Homo sapiens (human)
cAMP transportMultidrug resistance-associated protein 4Homo sapiens (human)
leukotriene transportMultidrug resistance-associated protein 4Homo sapiens (human)
monoatomic anion transmembrane transportMultidrug resistance-associated protein 4Homo sapiens (human)
export across plasma membraneMultidrug resistance-associated protein 4Homo sapiens (human)
transport across blood-brain barrierMultidrug resistance-associated protein 4Homo sapiens (human)
guanine nucleotide transmembrane transportMultidrug resistance-associated protein 4Homo sapiens (human)
fatty acid metabolic processBile salt export pumpHomo sapiens (human)
bile acid biosynthetic processBile salt export pumpHomo sapiens (human)
xenobiotic metabolic processBile salt export pumpHomo sapiens (human)
xenobiotic transmembrane transportBile salt export pumpHomo sapiens (human)
response to oxidative stressBile salt export pumpHomo sapiens (human)
bile acid metabolic processBile salt export pumpHomo sapiens (human)
response to organic cyclic compoundBile salt export pumpHomo sapiens (human)
bile acid and bile salt transportBile salt export pumpHomo sapiens (human)
canalicular bile acid transportBile salt export pumpHomo sapiens (human)
protein ubiquitinationBile salt export pumpHomo sapiens (human)
regulation of fatty acid beta-oxidationBile salt export pumpHomo sapiens (human)
carbohydrate transmembrane transportBile salt export pumpHomo sapiens (human)
bile acid signaling pathwayBile salt export pumpHomo sapiens (human)
cholesterol homeostasisBile salt export pumpHomo sapiens (human)
response to estrogenBile salt export pumpHomo sapiens (human)
response to ethanolBile salt export pumpHomo sapiens (human)
xenobiotic export from cellBile salt export pumpHomo sapiens (human)
lipid homeostasisBile salt export pumpHomo sapiens (human)
phospholipid homeostasisBile salt export pumpHomo sapiens (human)
positive regulation of bile acid secretionBile salt export pumpHomo sapiens (human)
regulation of bile acid metabolic processBile salt export pumpHomo sapiens (human)
transmembrane transportBile salt export pumpHomo sapiens (human)
chemotaxisComplement C5Homo sapiens (human)
inflammatory responseComplement C5Homo sapiens (human)
complement activation, alternative pathwayComplement C5Homo sapiens (human)
complement activation, classical pathwayComplement C5Homo sapiens (human)
cell surface receptor signaling pathwayComplement C5Homo sapiens (human)
G protein-coupled receptor signaling pathwayComplement C5Homo sapiens (human)
positive regulation of vascular endothelial growth factor productionComplement C5Homo sapiens (human)
negative regulation of macrophage chemotaxisComplement C5Homo sapiens (human)
killing of cells of another organismComplement C5Homo sapiens (human)
positive regulation of chemokine productionComplement C5Homo sapiens (human)
cell chemotaxisComplement C5Homo sapiens (human)
negative regulation of cell population proliferationCellular tumor antigen p53Homo sapiens (human)
regulation of cell cycleCellular tumor antigen p53Homo sapiens (human)
regulation of cell cycle G2/M phase transitionCellular tumor antigen p53Homo sapiens (human)
DNA damage responseCellular tumor antigen p53Homo sapiens (human)
ER overload responseCellular tumor antigen p53Homo sapiens (human)
cellular response to glucose starvationCellular tumor antigen p53Homo sapiens (human)
intrinsic apoptotic signaling pathway in response to DNA damage by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
regulation of apoptotic processCellular tumor antigen p53Homo sapiens (human)
positive regulation of transcription by RNA polymerase IICellular tumor antigen p53Homo sapiens (human)
positive regulation of miRNA transcriptionCellular tumor antigen p53Homo sapiens (human)
negative regulation of transcription by RNA polymerase IICellular tumor antigen p53Homo sapiens (human)
mitophagyCellular tumor antigen p53Homo sapiens (human)
in utero embryonic developmentCellular tumor antigen p53Homo sapiens (human)
somitogenesisCellular tumor antigen p53Homo sapiens (human)
release of cytochrome c from mitochondriaCellular tumor antigen p53Homo sapiens (human)
hematopoietic progenitor cell differentiationCellular tumor antigen p53Homo sapiens (human)
T cell proliferation involved in immune responseCellular tumor antigen p53Homo sapiens (human)
B cell lineage commitmentCellular tumor antigen p53Homo sapiens (human)
T cell lineage commitmentCellular tumor antigen p53Homo sapiens (human)
response to ischemiaCellular tumor antigen p53Homo sapiens (human)
nucleotide-excision repairCellular tumor antigen p53Homo sapiens (human)
double-strand break repairCellular tumor antigen p53Homo sapiens (human)
regulation of DNA-templated transcriptionCellular tumor antigen p53Homo sapiens (human)
regulation of transcription by RNA polymerase IICellular tumor antigen p53Homo sapiens (human)
protein import into nucleusCellular tumor antigen p53Homo sapiens (human)
autophagyCellular tumor antigen p53Homo sapiens (human)
DNA damage responseCellular tumor antigen p53Homo sapiens (human)
DNA damage response, signal transduction by p53 class mediator resulting in cell cycle arrestCellular tumor antigen p53Homo sapiens (human)
DNA damage response, signal transduction by p53 class mediator resulting in transcription of p21 class mediatorCellular tumor antigen p53Homo sapiens (human)
transforming growth factor beta receptor signaling pathwayCellular tumor antigen p53Homo sapiens (human)
Ras protein signal transductionCellular tumor antigen p53Homo sapiens (human)
gastrulationCellular tumor antigen p53Homo sapiens (human)
neuroblast proliferationCellular tumor antigen p53Homo sapiens (human)
negative regulation of neuroblast proliferationCellular tumor antigen p53Homo sapiens (human)
protein localizationCellular tumor antigen p53Homo sapiens (human)
negative regulation of DNA replicationCellular tumor antigen p53Homo sapiens (human)
negative regulation of cell population proliferationCellular tumor antigen p53Homo sapiens (human)
determination of adult lifespanCellular tumor antigen p53Homo sapiens (human)
mRNA transcriptionCellular tumor antigen p53Homo sapiens (human)
rRNA transcriptionCellular tumor antigen p53Homo sapiens (human)
response to salt stressCellular tumor antigen p53Homo sapiens (human)
response to inorganic substanceCellular tumor antigen p53Homo sapiens (human)
response to X-rayCellular tumor antigen p53Homo sapiens (human)
response to gamma radiationCellular tumor antigen p53Homo sapiens (human)
positive regulation of gene expressionCellular tumor antigen p53Homo sapiens (human)
cardiac muscle cell apoptotic processCellular tumor antigen p53Homo sapiens (human)
positive regulation of cardiac muscle cell apoptotic processCellular tumor antigen p53Homo sapiens (human)
glial cell proliferationCellular tumor antigen p53Homo sapiens (human)
viral processCellular tumor antigen p53Homo sapiens (human)
glucose catabolic process to lactate via pyruvateCellular tumor antigen p53Homo sapiens (human)
cerebellum developmentCellular tumor antigen p53Homo sapiens (human)
negative regulation of cell growthCellular tumor antigen p53Homo sapiens (human)
DNA damage response, signal transduction by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
negative regulation of transforming growth factor beta receptor signaling pathwayCellular tumor antigen p53Homo sapiens (human)
mitotic G1 DNA damage checkpoint signalingCellular tumor antigen p53Homo sapiens (human)
negative regulation of telomere maintenance via telomeraseCellular tumor antigen p53Homo sapiens (human)
T cell differentiation in thymusCellular tumor antigen p53Homo sapiens (human)
tumor necrosis factor-mediated signaling pathwayCellular tumor antigen p53Homo sapiens (human)
regulation of tissue remodelingCellular tumor antigen p53Homo sapiens (human)
cellular response to UVCellular tumor antigen p53Homo sapiens (human)
multicellular organism growthCellular tumor antigen p53Homo sapiens (human)
positive regulation of mitochondrial membrane permeabilityCellular tumor antigen p53Homo sapiens (human)
cellular response to glucose starvationCellular tumor antigen p53Homo sapiens (human)
intrinsic apoptotic signaling pathway in response to DNA damage by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
positive regulation of apoptotic processCellular tumor antigen p53Homo sapiens (human)
negative regulation of apoptotic processCellular tumor antigen p53Homo sapiens (human)
entrainment of circadian clock by photoperiodCellular tumor antigen p53Homo sapiens (human)
mitochondrial DNA repairCellular tumor antigen p53Homo sapiens (human)
regulation of DNA damage response, signal transduction by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
positive regulation of neuron apoptotic processCellular tumor antigen p53Homo sapiens (human)
transcription initiation-coupled chromatin remodelingCellular tumor antigen p53Homo sapiens (human)
negative regulation of proteolysisCellular tumor antigen p53Homo sapiens (human)
negative regulation of DNA-templated transcriptionCellular tumor antigen p53Homo sapiens (human)
positive regulation of DNA-templated transcriptionCellular tumor antigen p53Homo sapiens (human)
positive regulation of RNA polymerase II transcription preinitiation complex assemblyCellular tumor antigen p53Homo sapiens (human)
positive regulation of transcription by RNA polymerase IICellular tumor antigen p53Homo sapiens (human)
response to antibioticCellular tumor antigen p53Homo sapiens (human)
fibroblast proliferationCellular tumor antigen p53Homo sapiens (human)
negative regulation of fibroblast proliferationCellular tumor antigen p53Homo sapiens (human)
circadian behaviorCellular tumor antigen p53Homo sapiens (human)
bone marrow developmentCellular tumor antigen p53Homo sapiens (human)
embryonic organ developmentCellular tumor antigen p53Homo sapiens (human)
positive regulation of peptidyl-tyrosine phosphorylationCellular tumor antigen p53Homo sapiens (human)
protein stabilizationCellular tumor antigen p53Homo sapiens (human)
negative regulation of helicase activityCellular tumor antigen p53Homo sapiens (human)
protein tetramerizationCellular tumor antigen p53Homo sapiens (human)
chromosome organizationCellular tumor antigen p53Homo sapiens (human)
neuron apoptotic processCellular tumor antigen p53Homo sapiens (human)
regulation of cell cycleCellular tumor antigen p53Homo sapiens (human)
hematopoietic stem cell differentiationCellular tumor antigen p53Homo sapiens (human)
negative regulation of glial cell proliferationCellular tumor antigen p53Homo sapiens (human)
type II interferon-mediated signaling pathwayCellular tumor antigen p53Homo sapiens (human)
cardiac septum morphogenesisCellular tumor antigen p53Homo sapiens (human)
positive regulation of programmed necrotic cell deathCellular tumor antigen p53Homo sapiens (human)
protein-containing complex assemblyCellular tumor antigen p53Homo sapiens (human)
intrinsic apoptotic signaling pathway in response to endoplasmic reticulum stressCellular tumor antigen p53Homo sapiens (human)
thymocyte apoptotic processCellular tumor antigen p53Homo sapiens (human)
positive regulation of thymocyte apoptotic processCellular tumor antigen p53Homo sapiens (human)
necroptotic processCellular tumor antigen p53Homo sapiens (human)
cellular response to hypoxiaCellular tumor antigen p53Homo sapiens (human)
cellular response to xenobiotic stimulusCellular tumor antigen p53Homo sapiens (human)
cellular response to ionizing radiationCellular tumor antigen p53Homo sapiens (human)
cellular response to gamma radiationCellular tumor antigen p53Homo sapiens (human)
cellular response to UV-CCellular tumor antigen p53Homo sapiens (human)
stem cell proliferationCellular tumor antigen p53Homo sapiens (human)
signal transduction by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
intrinsic apoptotic signaling pathway by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
reactive oxygen species metabolic processCellular tumor antigen p53Homo sapiens (human)
cellular response to actinomycin DCellular tumor antigen p53Homo sapiens (human)
positive regulation of release of cytochrome c from mitochondriaCellular tumor antigen p53Homo sapiens (human)
cellular senescenceCellular tumor antigen p53Homo sapiens (human)
replicative senescenceCellular tumor antigen p53Homo sapiens (human)
oxidative stress-induced premature senescenceCellular tumor antigen p53Homo sapiens (human)
intrinsic apoptotic signaling pathwayCellular tumor antigen p53Homo sapiens (human)
oligodendrocyte apoptotic processCellular tumor antigen p53Homo sapiens (human)
positive regulation of execution phase of apoptosisCellular tumor antigen p53Homo sapiens (human)
negative regulation of mitophagyCellular tumor antigen p53Homo sapiens (human)
regulation of mitochondrial membrane permeability involved in apoptotic processCellular tumor antigen p53Homo sapiens (human)
regulation of intrinsic apoptotic signaling pathway by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
positive regulation of miRNA transcriptionCellular tumor antigen p53Homo sapiens (human)
negative regulation of G1 to G0 transitionCellular tumor antigen p53Homo sapiens (human)
negative regulation of miRNA processingCellular tumor antigen p53Homo sapiens (human)
negative regulation of glucose catabolic process to lactate via pyruvateCellular tumor antigen p53Homo sapiens (human)
negative regulation of pentose-phosphate shuntCellular tumor antigen p53Homo sapiens (human)
intrinsic apoptotic signaling pathway in response to hypoxiaCellular tumor antigen p53Homo sapiens (human)
regulation of fibroblast apoptotic processCellular tumor antigen p53Homo sapiens (human)
negative regulation of reactive oxygen species metabolic processCellular tumor antigen p53Homo sapiens (human)
positive regulation of reactive oxygen species metabolic processCellular tumor antigen p53Homo sapiens (human)
negative regulation of stem cell proliferationCellular tumor antigen p53Homo sapiens (human)
positive regulation of cellular senescenceCellular tumor antigen p53Homo sapiens (human)
positive regulation of intrinsic apoptotic signaling pathwayCellular tumor antigen p53Homo sapiens (human)
prostaglandin biosynthetic processProstaglandin G/H synthase 1Homo sapiens (human)
response to oxidative stressProstaglandin G/H synthase 1Homo sapiens (human)
regulation of blood pressureProstaglandin G/H synthase 1Homo sapiens (human)
cyclooxygenase pathwayProstaglandin G/H synthase 1Homo sapiens (human)
regulation of cell population proliferationProstaglandin G/H synthase 1Homo sapiens (human)
cellular oxidant detoxificationProstaglandin G/H synthase 1Homo sapiens (human)
prostaglandin biosynthetic processProstaglandin G/H synthase 2Homo sapiens (human)
angiogenesisProstaglandin G/H synthase 2Homo sapiens (human)
response to oxidative stressProstaglandin G/H synthase 2Homo sapiens (human)
embryo implantationProstaglandin G/H synthase 2Homo sapiens (human)
learningProstaglandin G/H synthase 2Homo sapiens (human)
memoryProstaglandin G/H synthase 2Homo sapiens (human)
regulation of blood pressureProstaglandin G/H synthase 2Homo sapiens (human)
negative regulation of cell population proliferationProstaglandin G/H synthase 2Homo sapiens (human)
response to xenobiotic stimulusProstaglandin G/H synthase 2Homo sapiens (human)
response to nematodeProstaglandin G/H synthase 2Homo sapiens (human)
response to fructoseProstaglandin G/H synthase 2Homo sapiens (human)
response to manganese ionProstaglandin G/H synthase 2Homo sapiens (human)
positive regulation of vascular endothelial growth factor productionProstaglandin G/H synthase 2Homo sapiens (human)
cyclooxygenase pathwayProstaglandin G/H synthase 2Homo sapiens (human)
bone mineralizationProstaglandin G/H synthase 2Homo sapiens (human)
positive regulation of prostaglandin biosynthetic processProstaglandin G/H synthase 2Homo sapiens (human)
positive regulation of fever generationProstaglandin G/H synthase 2Homo sapiens (human)
positive regulation of synaptic plasticityProstaglandin G/H synthase 2Homo sapiens (human)
negative regulation of synaptic transmission, dopaminergicProstaglandin G/H synthase 2Homo sapiens (human)
prostaglandin secretionProstaglandin G/H synthase 2Homo sapiens (human)
response to estradiolProstaglandin G/H synthase 2Homo sapiens (human)
response to lipopolysaccharideProstaglandin G/H synthase 2Homo sapiens (human)
positive regulation of peptidyl-serine phosphorylationProstaglandin G/H synthase 2Homo sapiens (human)
response to vitamin DProstaglandin G/H synthase 2Homo sapiens (human)
cellular response to heatProstaglandin G/H synthase 2Homo sapiens (human)
response to tumor necrosis factorProstaglandin G/H synthase 2Homo sapiens (human)
maintenance of blood-brain barrierProstaglandin G/H synthase 2Homo sapiens (human)
positive regulation of protein import into nucleusProstaglandin G/H synthase 2Homo sapiens (human)
hair cycleProstaglandin G/H synthase 2Homo sapiens (human)
positive regulation of apoptotic processProstaglandin G/H synthase 2Homo sapiens (human)
positive regulation of nitric oxide biosynthetic processProstaglandin G/H synthase 2Homo sapiens (human)
negative regulation of cell cycleProstaglandin G/H synthase 2Homo sapiens (human)
positive regulation of vasoconstrictionProstaglandin G/H synthase 2Homo sapiens (human)
negative regulation of smooth muscle contractionProstaglandin G/H synthase 2Homo sapiens (human)
positive regulation of smooth muscle contractionProstaglandin G/H synthase 2Homo sapiens (human)
decidualizationProstaglandin G/H synthase 2Homo sapiens (human)
positive regulation of smooth muscle cell proliferationProstaglandin G/H synthase 2Homo sapiens (human)
regulation of inflammatory responseProstaglandin G/H synthase 2Homo sapiens (human)
brown fat cell differentiationProstaglandin G/H synthase 2Homo sapiens (human)
response to glucocorticoidProstaglandin G/H synthase 2Homo sapiens (human)
negative regulation of calcium ion transportProstaglandin G/H synthase 2Homo sapiens (human)
positive regulation of synaptic transmission, glutamatergicProstaglandin G/H synthase 2Homo sapiens (human)
response to fatty acidProstaglandin G/H synthase 2Homo sapiens (human)
cellular response to mechanical stimulusProstaglandin G/H synthase 2Homo sapiens (human)
cellular response to lead ionProstaglandin G/H synthase 2Homo sapiens (human)
cellular response to ATPProstaglandin G/H synthase 2Homo sapiens (human)
cellular response to hypoxiaProstaglandin G/H synthase 2Homo sapiens (human)
cellular response to non-ionic osmotic stressProstaglandin G/H synthase 2Homo sapiens (human)
cellular response to fluid shear stressProstaglandin G/H synthase 2Homo sapiens (human)
positive regulation of transforming growth factor beta productionProstaglandin G/H synthase 2Homo sapiens (human)
positive regulation of cell migration involved in sprouting angiogenesisProstaglandin G/H synthase 2Homo sapiens (human)
positive regulation of fibroblast growth factor productionProstaglandin G/H synthase 2Homo sapiens (human)
positive regulation of brown fat cell differentiationProstaglandin G/H synthase 2Homo sapiens (human)
positive regulation of platelet-derived growth factor productionProstaglandin G/H synthase 2Homo sapiens (human)
cellular oxidant detoxificationProstaglandin G/H synthase 2Homo sapiens (human)
regulation of neuroinflammatory responseProstaglandin G/H synthase 2Homo sapiens (human)
negative regulation of intrinsic apoptotic signaling pathway in response to osmotic stressProstaglandin G/H synthase 2Homo sapiens (human)
cellular response to homocysteineProstaglandin G/H synthase 2Homo sapiens (human)
response to angiotensinProstaglandin G/H synthase 2Homo sapiens (human)
negative regulation of protein phosphorylationTAR DNA-binding protein 43Homo sapiens (human)
mRNA processingTAR DNA-binding protein 43Homo sapiens (human)
RNA splicingTAR DNA-binding protein 43Homo sapiens (human)
negative regulation of gene expressionTAR DNA-binding protein 43Homo sapiens (human)
regulation of protein stabilityTAR DNA-binding protein 43Homo sapiens (human)
positive regulation of insulin secretionTAR DNA-binding protein 43Homo sapiens (human)
response to endoplasmic reticulum stressTAR DNA-binding protein 43Homo sapiens (human)
positive regulation of protein import into nucleusTAR DNA-binding protein 43Homo sapiens (human)
regulation of circadian rhythmTAR DNA-binding protein 43Homo sapiens (human)
regulation of apoptotic processTAR DNA-binding protein 43Homo sapiens (human)
negative regulation by host of viral transcriptionTAR DNA-binding protein 43Homo sapiens (human)
rhythmic processTAR DNA-binding protein 43Homo sapiens (human)
regulation of cell cycleTAR DNA-binding protein 43Homo sapiens (human)
3'-UTR-mediated mRNA destabilizationTAR DNA-binding protein 43Homo sapiens (human)
3'-UTR-mediated mRNA stabilizationTAR DNA-binding protein 43Homo sapiens (human)
nuclear inner membrane organizationTAR DNA-binding protein 43Homo sapiens (human)
amyloid fibril formationTAR DNA-binding protein 43Homo sapiens (human)
regulation of gene expressionTAR DNA-binding protein 43Homo sapiens (human)
xenobiotic metabolic processCanalicular multispecific organic anion transporter 1Homo sapiens (human)
xenobiotic transmembrane transportCanalicular multispecific organic anion transporter 1Homo sapiens (human)
negative regulation of gene expressionCanalicular multispecific organic anion transporter 1Homo sapiens (human)
bile acid and bile salt transportCanalicular multispecific organic anion transporter 1Homo sapiens (human)
bilirubin transportCanalicular multispecific organic anion transporter 1Homo sapiens (human)
heme catabolic processCanalicular multispecific organic anion transporter 1Homo sapiens (human)
xenobiotic export from cellCanalicular multispecific organic anion transporter 1Homo sapiens (human)
transmembrane transportCanalicular multispecific organic anion transporter 1Homo sapiens (human)
transepithelial transportCanalicular multispecific organic anion transporter 1Homo sapiens (human)
leukotriene transportCanalicular multispecific organic anion transporter 1Homo sapiens (human)
monoatomic anion transmembrane transportCanalicular multispecific organic anion transporter 1Homo sapiens (human)
transport across blood-brain barrierCanalicular multispecific organic anion transporter 1Homo sapiens (human)
xenobiotic transport across blood-brain barrierCanalicular multispecific organic anion transporter 1Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (71)

Processvia Protein(s)Taxonomy
ATP bindingATP-binding cassette sub-family C member 3Homo sapiens (human)
ABC-type xenobiotic transporter activityATP-binding cassette sub-family C member 3Homo sapiens (human)
glucuronoside transmembrane transporter activityATP-binding cassette sub-family C member 3Homo sapiens (human)
ABC-type glutathione S-conjugate transporter activityATP-binding cassette sub-family C member 3Homo sapiens (human)
ABC-type bile acid transporter activityATP-binding cassette sub-family C member 3Homo sapiens (human)
ATP hydrolysis activityATP-binding cassette sub-family C member 3Homo sapiens (human)
ATPase-coupled transmembrane transporter activityATP-binding cassette sub-family C member 3Homo sapiens (human)
xenobiotic transmembrane transporter activityATP-binding cassette sub-family C member 3Homo sapiens (human)
ATPase-coupled inorganic anion transmembrane transporter activityATP-binding cassette sub-family C member 3Homo sapiens (human)
icosanoid transmembrane transporter activityATP-binding cassette sub-family C member 3Homo sapiens (human)
ABC-type transporter activityATP-binding cassette sub-family C member 3Homo sapiens (human)
guanine nucleotide transmembrane transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
protein bindingMultidrug resistance-associated protein 4Homo sapiens (human)
ATP bindingMultidrug resistance-associated protein 4Homo sapiens (human)
ABC-type xenobiotic transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
prostaglandin transmembrane transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
urate transmembrane transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
purine nucleotide transmembrane transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
ABC-type glutathione S-conjugate transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
ABC-type bile acid transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
efflux transmembrane transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
15-hydroxyprostaglandin dehydrogenase (NAD+) activityMultidrug resistance-associated protein 4Homo sapiens (human)
ATP hydrolysis activityMultidrug resistance-associated protein 4Homo sapiens (human)
glutathione transmembrane transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
ATPase-coupled transmembrane transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
xenobiotic transmembrane transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
ATPase-coupled inorganic anion transmembrane transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
ABC-type transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
protein bindingBile salt export pumpHomo sapiens (human)
ATP bindingBile salt export pumpHomo sapiens (human)
ABC-type xenobiotic transporter activityBile salt export pumpHomo sapiens (human)
bile acid transmembrane transporter activityBile salt export pumpHomo sapiens (human)
canalicular bile acid transmembrane transporter activityBile salt export pumpHomo sapiens (human)
carbohydrate transmembrane transporter activityBile salt export pumpHomo sapiens (human)
ABC-type bile acid transporter activityBile salt export pumpHomo sapiens (human)
ATP hydrolysis activityBile salt export pumpHomo sapiens (human)
endopeptidase inhibitor activityComplement C5Homo sapiens (human)
signaling receptor bindingComplement C5Homo sapiens (human)
protein bindingComplement C5Homo sapiens (human)
chemokine activityComplement C5Homo sapiens (human)
transcription cis-regulatory region bindingCellular tumor antigen p53Homo sapiens (human)
RNA polymerase II cis-regulatory region sequence-specific DNA bindingCellular tumor antigen p53Homo sapiens (human)
DNA-binding transcription factor activity, RNA polymerase II-specificCellular tumor antigen p53Homo sapiens (human)
cis-regulatory region sequence-specific DNA bindingCellular tumor antigen p53Homo sapiens (human)
core promoter sequence-specific DNA bindingCellular tumor antigen p53Homo sapiens (human)
TFIID-class transcription factor complex bindingCellular tumor antigen p53Homo sapiens (human)
DNA-binding transcription repressor activity, RNA polymerase II-specificCellular tumor antigen p53Homo sapiens (human)
DNA-binding transcription activator activity, RNA polymerase II-specificCellular tumor antigen p53Homo sapiens (human)
protease bindingCellular tumor antigen p53Homo sapiens (human)
p53 bindingCellular tumor antigen p53Homo sapiens (human)
DNA bindingCellular tumor antigen p53Homo sapiens (human)
chromatin bindingCellular tumor antigen p53Homo sapiens (human)
DNA-binding transcription factor activityCellular tumor antigen p53Homo sapiens (human)
mRNA 3'-UTR bindingCellular tumor antigen p53Homo sapiens (human)
copper ion bindingCellular tumor antigen p53Homo sapiens (human)
protein bindingCellular tumor antigen p53Homo sapiens (human)
zinc ion bindingCellular tumor antigen p53Homo sapiens (human)
enzyme bindingCellular tumor antigen p53Homo sapiens (human)
receptor tyrosine kinase bindingCellular tumor antigen p53Homo sapiens (human)
ubiquitin protein ligase bindingCellular tumor antigen p53Homo sapiens (human)
histone deacetylase regulator activityCellular tumor antigen p53Homo sapiens (human)
ATP-dependent DNA/DNA annealing activityCellular tumor antigen p53Homo sapiens (human)
identical protein bindingCellular tumor antigen p53Homo sapiens (human)
histone deacetylase bindingCellular tumor antigen p53Homo sapiens (human)
protein heterodimerization activityCellular tumor antigen p53Homo sapiens (human)
protein-folding chaperone bindingCellular tumor antigen p53Homo sapiens (human)
protein phosphatase 2A bindingCellular tumor antigen p53Homo sapiens (human)
RNA polymerase II-specific DNA-binding transcription factor bindingCellular tumor antigen p53Homo sapiens (human)
14-3-3 protein bindingCellular tumor antigen p53Homo sapiens (human)
MDM2/MDM4 family protein bindingCellular tumor antigen p53Homo sapiens (human)
disordered domain specific bindingCellular tumor antigen p53Homo sapiens (human)
general transcription initiation factor bindingCellular tumor antigen p53Homo sapiens (human)
molecular function activator activityCellular tumor antigen p53Homo sapiens (human)
promoter-specific chromatin bindingCellular tumor antigen p53Homo sapiens (human)
peroxidase activityProstaglandin G/H synthase 1Homo sapiens (human)
prostaglandin-endoperoxide synthase activityProstaglandin G/H synthase 1Homo sapiens (human)
protein bindingProstaglandin G/H synthase 1Homo sapiens (human)
heme bindingProstaglandin G/H synthase 1Homo sapiens (human)
metal ion bindingProstaglandin G/H synthase 1Homo sapiens (human)
oxidoreductase activity, acting on single donors with incorporation of molecular oxygen, incorporation of two atoms of oxygenProstaglandin G/H synthase 1Homo sapiens (human)
peroxidase activityProstaglandin G/H synthase 2Homo sapiens (human)
prostaglandin-endoperoxide synthase activityProstaglandin G/H synthase 2Homo sapiens (human)
protein bindingProstaglandin G/H synthase 2Homo sapiens (human)
enzyme bindingProstaglandin G/H synthase 2Homo sapiens (human)
heme bindingProstaglandin G/H synthase 2Homo sapiens (human)
protein homodimerization activityProstaglandin G/H synthase 2Homo sapiens (human)
metal ion bindingProstaglandin G/H synthase 2Homo sapiens (human)
oxidoreductase activity, acting on single donors with incorporation of molecular oxygen, incorporation of two atoms of oxygenProstaglandin G/H synthase 2Homo sapiens (human)
RNA polymerase II cis-regulatory region sequence-specific DNA bindingTAR DNA-binding protein 43Homo sapiens (human)
DNA bindingTAR DNA-binding protein 43Homo sapiens (human)
double-stranded DNA bindingTAR DNA-binding protein 43Homo sapiens (human)
RNA bindingTAR DNA-binding protein 43Homo sapiens (human)
mRNA 3'-UTR bindingTAR DNA-binding protein 43Homo sapiens (human)
protein bindingTAR DNA-binding protein 43Homo sapiens (human)
lipid bindingTAR DNA-binding protein 43Homo sapiens (human)
identical protein bindingTAR DNA-binding protein 43Homo sapiens (human)
pre-mRNA intronic bindingTAR DNA-binding protein 43Homo sapiens (human)
molecular condensate scaffold activityTAR DNA-binding protein 43Homo sapiens (human)
protein bindingCanalicular multispecific organic anion transporter 1Homo sapiens (human)
ATP bindingCanalicular multispecific organic anion transporter 1Homo sapiens (human)
organic anion transmembrane transporter activityCanalicular multispecific organic anion transporter 1Homo sapiens (human)
ABC-type xenobiotic transporter activityCanalicular multispecific organic anion transporter 1Homo sapiens (human)
bilirubin transmembrane transporter activityCanalicular multispecific organic anion transporter 1Homo sapiens (human)
ABC-type glutathione S-conjugate transporter activityCanalicular multispecific organic anion transporter 1Homo sapiens (human)
ATP hydrolysis activityCanalicular multispecific organic anion transporter 1Homo sapiens (human)
ATPase-coupled transmembrane transporter activityCanalicular multispecific organic anion transporter 1Homo sapiens (human)
xenobiotic transmembrane transporter activityCanalicular multispecific organic anion transporter 1Homo sapiens (human)
ATPase-coupled inorganic anion transmembrane transporter activityCanalicular multispecific organic anion transporter 1Homo sapiens (human)
ABC-type transporter activityCanalicular multispecific organic anion transporter 1Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (51)

Processvia Protein(s)Taxonomy
plasma membraneATP-binding cassette sub-family C member 3Homo sapiens (human)
basal plasma membraneATP-binding cassette sub-family C member 3Homo sapiens (human)
basolateral plasma membraneATP-binding cassette sub-family C member 3Homo sapiens (human)
membraneATP-binding cassette sub-family C member 3Homo sapiens (human)
nucleolusMultidrug resistance-associated protein 4Homo sapiens (human)
Golgi apparatusMultidrug resistance-associated protein 4Homo sapiens (human)
plasma membraneMultidrug resistance-associated protein 4Homo sapiens (human)
membraneMultidrug resistance-associated protein 4Homo sapiens (human)
basolateral plasma membraneMultidrug resistance-associated protein 4Homo sapiens (human)
apical plasma membraneMultidrug resistance-associated protein 4Homo sapiens (human)
platelet dense granule membraneMultidrug resistance-associated protein 4Homo sapiens (human)
external side of apical plasma membraneMultidrug resistance-associated protein 4Homo sapiens (human)
plasma membraneMultidrug resistance-associated protein 4Homo sapiens (human)
basolateral plasma membraneBile salt export pumpHomo sapiens (human)
Golgi membraneBile salt export pumpHomo sapiens (human)
endosomeBile salt export pumpHomo sapiens (human)
plasma membraneBile salt export pumpHomo sapiens (human)
cell surfaceBile salt export pumpHomo sapiens (human)
apical plasma membraneBile salt export pumpHomo sapiens (human)
intercellular canaliculusBile salt export pumpHomo sapiens (human)
intracellular canaliculusBile salt export pumpHomo sapiens (human)
recycling endosomeBile salt export pumpHomo sapiens (human)
recycling endosome membraneBile salt export pumpHomo sapiens (human)
extracellular exosomeBile salt export pumpHomo sapiens (human)
membraneBile salt export pumpHomo sapiens (human)
extracellular regionComplement C5Homo sapiens (human)
extracellular spaceComplement C5Homo sapiens (human)
extracellular exosomeComplement C5Homo sapiens (human)
membrane attack complexComplement C5Homo sapiens (human)
nuclear bodyCellular tumor antigen p53Homo sapiens (human)
nucleusCellular tumor antigen p53Homo sapiens (human)
nucleoplasmCellular tumor antigen p53Homo sapiens (human)
replication forkCellular tumor antigen p53Homo sapiens (human)
nucleolusCellular tumor antigen p53Homo sapiens (human)
cytoplasmCellular tumor antigen p53Homo sapiens (human)
mitochondrionCellular tumor antigen p53Homo sapiens (human)
mitochondrial matrixCellular tumor antigen p53Homo sapiens (human)
endoplasmic reticulumCellular tumor antigen p53Homo sapiens (human)
centrosomeCellular tumor antigen p53Homo sapiens (human)
cytosolCellular tumor antigen p53Homo sapiens (human)
nuclear matrixCellular tumor antigen p53Homo sapiens (human)
PML bodyCellular tumor antigen p53Homo sapiens (human)
transcription repressor complexCellular tumor antigen p53Homo sapiens (human)
site of double-strand breakCellular tumor antigen p53Homo sapiens (human)
germ cell nucleusCellular tumor antigen p53Homo sapiens (human)
chromatinCellular tumor antigen p53Homo sapiens (human)
transcription regulator complexCellular tumor antigen p53Homo sapiens (human)
protein-containing complexCellular tumor antigen p53Homo sapiens (human)
photoreceptor outer segmentProstaglandin G/H synthase 1Homo sapiens (human)
cytoplasmProstaglandin G/H synthase 1Homo sapiens (human)
endoplasmic reticulum membraneProstaglandin G/H synthase 1Homo sapiens (human)
Golgi apparatusProstaglandin G/H synthase 1Homo sapiens (human)
intracellular membrane-bounded organelleProstaglandin G/H synthase 1Homo sapiens (human)
extracellular exosomeProstaglandin G/H synthase 1Homo sapiens (human)
cytoplasmProstaglandin G/H synthase 1Homo sapiens (human)
neuron projectionProstaglandin G/H synthase 1Homo sapiens (human)
nuclear inner membraneProstaglandin G/H synthase 2Homo sapiens (human)
nuclear outer membraneProstaglandin G/H synthase 2Homo sapiens (human)
cytoplasmProstaglandin G/H synthase 2Homo sapiens (human)
endoplasmic reticulumProstaglandin G/H synthase 2Homo sapiens (human)
endoplasmic reticulum lumenProstaglandin G/H synthase 2Homo sapiens (human)
endoplasmic reticulum membraneProstaglandin G/H synthase 2Homo sapiens (human)
caveolaProstaglandin G/H synthase 2Homo sapiens (human)
neuron projectionProstaglandin G/H synthase 2Homo sapiens (human)
protein-containing complexProstaglandin G/H synthase 2Homo sapiens (human)
neuron projectionProstaglandin G/H synthase 2Homo sapiens (human)
cytoplasmProstaglandin G/H synthase 2Homo sapiens (human)
intracellular non-membrane-bounded organelleTAR DNA-binding protein 43Homo sapiens (human)
nucleusTAR DNA-binding protein 43Homo sapiens (human)
nucleoplasmTAR DNA-binding protein 43Homo sapiens (human)
perichromatin fibrilsTAR DNA-binding protein 43Homo sapiens (human)
mitochondrionTAR DNA-binding protein 43Homo sapiens (human)
cytoplasmic stress granuleTAR DNA-binding protein 43Homo sapiens (human)
nuclear speckTAR DNA-binding protein 43Homo sapiens (human)
interchromatin granuleTAR DNA-binding protein 43Homo sapiens (human)
nucleoplasmTAR DNA-binding protein 43Homo sapiens (human)
chromatinTAR DNA-binding protein 43Homo sapiens (human)
plasma membraneCanalicular multispecific organic anion transporter 1Homo sapiens (human)
cell surfaceCanalicular multispecific organic anion transporter 1Homo sapiens (human)
apical plasma membraneCanalicular multispecific organic anion transporter 1Homo sapiens (human)
intercellular canaliculusCanalicular multispecific organic anion transporter 1Homo sapiens (human)
apical plasma membraneCanalicular multispecific organic anion transporter 1Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (123)

Assay IDTitleYearJournalArticle
AID588519A screen for compounds that inhibit viral RNA polymerase binding and polymerization activities2011Antiviral research, Sep, Volume: 91, Issue:3
High-throughput screening identification of poliovirus RNA-dependent RNA polymerase inhibitors.
AID540299A screen for compounds that inhibit the MenB enzyme of Mycobacterium tuberculosis2010Bioorganic & medicinal chemistry letters, Nov-01, Volume: 20, Issue:21
Synthesis and SAR studies of 1,4-benzoxazine MenB inhibitors: novel antibacterial agents against Mycobacterium tuberculosis.
AID1346987P-glycoprotein substrates identified in KB-8-5-11 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1346986P-glycoprotein substrates identified in KB-3-1 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1296008Cytotoxic Profiling of Annotated Libraries Using Quantitative High-Throughput Screening2020SLAS discovery : advancing life sciences R & D, 01, Volume: 25, Issue:1
Cytotoxic Profiling of Annotated and Diverse Chemical Libraries Using Quantitative High-Throughput Screening.
AID1079938Chronic liver disease either proven histopathologically, or through a chonic elevation of serum amino-transferase activity after 6 months. Value is number of references indexed. [column 'CHRON' in source]
AID251807Inhibition of CXCL8-induced chemotaxis of human polymorphonuclear cells at 10e-8 M2005Journal of medicinal chemistry, Jun-30, Volume: 48, Issue:13
2-Arylpropionic CXC chemokine receptor 1 (CXCR1) ligands as novel noncompetitive CXCL8 inhibitors.
AID1473741Inhibition of human MRP4 overexpressed in Sf9 cell membrane vesicles assessed as uptake of [3H]-estradiol-17beta-D-glucuronide in presence of ATP and GSH measured after 20 mins by membrane vesicle transport assay2013Toxicological sciences : an official journal of the Society of Toxicology, Nov, Volume: 136, Issue:1
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
AID977602Inhibition of sodium fluorescein uptake in OATP1B3-transfected CHO cells at an equimolar substrate-inhibitor concentration of 10 uM2013Molecular pharmacology, Jun, Volume: 83, Issue:6
Structure-based identification of OATP1B1/3 inhibitors.
AID1079940Granulomatous liver disease, proven histopathologically. Value is number of references indexed. [column 'GRAN' in source]
AID1473738Inhibition of human BSEP overexpressed in Sf9 cell membrane vesicles assessed as uptake of [3H]-taurocholate in presence of ATP measured after 15 to 20 mins by membrane vesicle transport assay2013Toxicological sciences : an official journal of the Society of Toxicology, Nov, Volume: 136, Issue:1
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
AID1473740Inhibition of human MRP3 overexpressed in Sf9 insect cell membrane vesicles assessed as uptake of [3H]-estradiol-17beta-D-glucuronide in presence of ATP and GSH measured after 10 mins by membrane vesicle transport assay2013Toxicological sciences : an official journal of the Society of Toxicology, Nov, Volume: 136, Issue:1
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
AID1827141Potentiation of oxacillin induced antibacterial activity against methicillin-resistant Staphylococcus aureus ATCC 43300 assessed as oxacillin MIC at 25 uM after 18 hrs by CLSI protocol based broth microdilution assay2022ACS medicinal chemistry letters, Mar-10, Volume: 13, Issue:3
Identification and Evaluation of Brominated Carbazoles as a Novel Antibiotic Adjuvant Scaffold in MRSA.
AID492859Inhibition of ovine COX1 after 5 mins2010Journal of medicinal chemistry, Jun-24, Volume: 53, Issue:12
Design, synthesis, and biological evaluation of a novel class of gamma-secretase modulators with PPARgamma activity.
AID614597Modulation of gamma-secretase expressed in CHO cells co-expressing human APP and wild type human presenilin-1 assessed as inhibition of amyloid beta42 production by ELISA2011Bioorganic & medicinal chemistry, Sep-15, Volume: 19, Issue:18
SAR studies of acidic dual γ-secretase/PPARγ modulators.
AID1827138Antibacterial activity against methicillin-resistant Staphylococcus aureus ATCC 43300 assessed as inhibition of bacterial growth after 18 hrs by CLSI protocol based broth microdilution assay2022ACS medicinal chemistry letters, Mar-10, Volume: 13, Issue:3
Identification and Evaluation of Brominated Carbazoles as a Novel Antibiotic Adjuvant Scaffold in MRSA.
AID220491Inhibitory activity against cell-free canine COX-22001Journal of medicinal chemistry, Mar-01, Volume: 44, Issue:5
Perspectives in animal health: old targets and new opportunities.
AID1079949Proposed mechanism(s) of liver damage. [column 'MEC' in source]
AID677462Dissociation constant, pKa of the compound2012European journal of medicinal chemistry, Jul, Volume: 53Self-organizing molecular field analysis of NSAIDs: assessment of pharmacokinetic and physicochemical properties using 3D-QSPkR approach.
AID1601161Binding affinity to human C5a assessed as dissociation constant after 1 hr by circular dichroism analysis2019Bioorganic & medicinal chemistry, 10-01, Volume: 27, Issue:19
A rational search for discovering potential neutraligands of human complement fragment 5a (
AID1079941Liver damage due to vascular disease: peliosis hepatitis, hepatic veno-occlusive disease, Budd-Chiari syndrome. Value is number of references indexed. [column 'VASC' in source]
AID274593Inhibition of beta amyloid protein 40 in human H4 cells overexpressing APP6952006Journal of medicinal chemistry, Dec-28, Volume: 49, Issue:26
Scaffold of the cyclooxygenase-2 (COX-2) inhibitor carprofen provides Alzheimer gamma-secretase modulators.
AID1079935Cytolytic liver toxicity, either proven histopathologically or where the ratio of maximal ALT or AST activity above normal to that of Alkaline Phosphatase is > 5 (see ACUTE). Value is number of references indexed. [column 'CYTOL' in source]
AID1079947Comments (NB not yet translated). [column 'COMMENTAIRES' in source]
AID588213Literature-mined compound from Fourches et al multi-species drug-induced liver injury (DILI) dataset, effect in non-rodents2010Chemical research in toxicology, Jan, Volume: 23, Issue:1
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
AID1079948Times to onset, minimal and maximal, observed in the indexed observations. [column 'DELAI' in source]
AID1601166Induction of human recombinant C5a unfolding by circular dichroism analysis2019Bioorganic & medicinal chemistry, 10-01, Volume: 27, Issue:19
A rational search for discovering potential neutraligands of human complement fragment 5a (
AID1827215Potentiation of oxacillin induced antibacterial activity against methicillin-resistant Staphylococcus aureus COL assessed as oxacillin MIC at 50 uM after 18 hrs by CLSI protocol based broth microdilution assay2022ACS medicinal chemistry letters, Mar-10, Volume: 13, Issue:3
Identification and Evaluation of Brominated Carbazoles as a Novel Antibiotic Adjuvant Scaffold in MRSA.
AID1079944Benign tumor, proven histopathologically. Value is number of references indexed. [column 'T.BEN' in source]
AID1079931Moderate liver toxicity, defined via clinical-chemistry results: ALT or AST serum activity 6 times the normal upper limit (N) or alkaline phosphatase serum activity of 1.7 N. Value is number of references indexed. [column 'BIOL' in source]
AID515780Intrinsic solubility of the compound in water2010Bioorganic & medicinal chemistry, Oct-01, Volume: 18, Issue:19
QSAR-based solubility model for drug-like compounds.
AID1827238Potentiation of oxacillin induced antibacterial activity against methicillin-resistant Staphylococcus aureus USA300 assessed as oxacillin MIC at 50 uM after 18 hrs by CLSI protocol based broth microdilution assay2022ACS medicinal chemistry letters, Mar-10, Volume: 13, Issue:3
Identification and Evaluation of Brominated Carbazoles as a Novel Antibiotic Adjuvant Scaffold in MRSA.
AID1827149Potentiation of oxacillin induced antibacterial activity against methicillin-resistant Staphylococcus aureus USA 100 assessed as fold change in oxacillin MIC at 50 uM after 18 hrs by CLSI protocol based broth microdilution assay2022ACS medicinal chemistry letters, Mar-10, Volume: 13, Issue:3
Identification and Evaluation of Brominated Carbazoles as a Novel Antibiotic Adjuvant Scaffold in MRSA.
AID251770Inhibition of lipopolysaccharide-induced PGE-2 production at 10e-5 M2005Journal of medicinal chemistry, Jun-30, Volume: 48, Issue:13
2-Arylpropionic CXC chemokine receptor 1 (CXCR1) ligands as novel noncompetitive CXCL8 inhibitors.
AID977599Inhibition of sodium fluorescein uptake in OATP1B1-transfected CHO cells at an equimolar substrate-inhibitor concentration of 10 uM2013Molecular pharmacology, Jun, Volume: 83, Issue:6
Structure-based identification of OATP1B1/3 inhibitors.
AID1601167Induction of human recombinant C5a destabilization assessed as protein structure helicity up to 10 uM by circular dichroism analysis (Rvb = 71%)2019Bioorganic & medicinal chemistry, 10-01, Volume: 27, Issue:19
A rational search for discovering potential neutraligands of human complement fragment 5a (
AID614602Inhibition of human recombinant COX-2 assessed as residual activity by measuring formation of 12-HHT from arachidonic acid by HPLC analysis2011Bioorganic & medicinal chemistry, Sep-15, Volume: 19, Issue:18
SAR studies of acidic dual γ-secretase/PPARγ modulators.
AID1079942Steatosis, proven histopathologically. Value is number of references indexed. [column 'STEAT' in source]
AID1079933Acute liver toxicity defined via clinical observations and clear clinical-chemistry results: serum ALT or AST activity > 6 N or serum alkaline phosphatases activity > 1.7 N. This category includes cytolytic, choleostatic and mixed liver toxicity. Value is
AID1827233Potentiation of oxacillin induced antibacterial activity against methicillin-resistant Staphylococcus aureus USA300 assessed as fold change in oxacillin MIC at 50 uM after 18 hrs by CLSI protocol based broth microdilution assay2022ACS medicinal chemistry letters, Mar-10, Volume: 13, Issue:3
Identification and Evaluation of Brominated Carbazoles as a Novel Antibiotic Adjuvant Scaffold in MRSA.
AID29648Oral bioavailability in dog2001Journal of medicinal chemistry, Mar-01, Volume: 44, Issue:5
Perspectives in animal health: old targets and new opportunities.
AID492867Modulation of gamma-secretase-mediated cleavage of human APP expressed in CHO cells with human presenilin-1 assessed as inhibition of amyloid beta42 production after 24 hrs by ELISA2010Journal of medicinal chemistry, Jun-24, Volume: 53, Issue:12
Design, synthesis, and biological evaluation of a novel class of gamma-secretase modulators with PPARgamma activity.
AID1079943Malignant tumor, proven histopathologically. Value is number of references indexed. [column 'T.MAL' in source]
AID692103Inhibition of gamma secretase assessed as reduction in Abeta42 production2011Journal of medicinal chemistry, Feb-10, Volume: 54, Issue:3
γ-Secretase modulators as potential disease modifying anti-Alzheimer's drugs.
AID220490Inhibitory activity against cell-free canine COX-12001Journal of medicinal chemistry, Mar-01, Volume: 44, Issue:5
Perspectives in animal health: old targets and new opportunities.
AID1601156Binding affinity to recombinant human C5a assessed as conformational change =< 1 uM at 4 degC incubated for 1 hr by circular dichroism analysis2019Bioorganic & medicinal chemistry, 10-01, Volume: 27, Issue:19
A rational search for discovering potential neutraligands of human complement fragment 5a (
AID362050Inhibition of COX1 in human whole blood2008Bioorganic & medicinal chemistry letters, Aug-15, Volume: 18, Issue:16
New NSAIDs-NO hybrid molecules with antiproliferative properties on human prostatic cancer cell lines.
AID1473739Inhibition of human MRP2 overexpressed in Sf9 cell membrane vesicles assessed as uptake of [3H]-estradiol-17beta-D-glucuronide in presence of ATP and GSH measured after 20 mins by membrane vesicle transport assay2013Toxicological sciences : an official journal of the Society of Toxicology, Nov, Volume: 136, Issue:1
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
AID1079936Choleostatic liver toxicity, either proven histopathologically or where the ratio of maximal ALT or AST activity above normal to that of Alkaline Phosphatase is < 2 (see ACUTE). Value is number of references indexed. [column 'CHOLE' in source]
AID588212Literature-mined compound from Fourches et al multi-species drug-induced liver injury (DILI) dataset, effect in rodents2010Chemical research in toxicology, Jan, Volume: 23, Issue:1
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
AID274592Inhibition of beta amyloid protein 38 in human H4 cells overexpressing APP6952006Journal of medicinal chemistry, Dec-28, Volume: 49, Issue:26
Scaffold of the cyclooxygenase-2 (COX-2) inhibitor carprofen provides Alzheimer gamma-secretase modulators.
AID1827210Potentiation of oxacillin induced antibacterial activity against methicillin-resistant Staphylococcus aureus COL assessed as fold change in oxacillin MIC at 50 uM after 18 hrs by CLSI protocol based broth microdilution assay2022ACS medicinal chemistry letters, Mar-10, Volume: 13, Issue:3
Identification and Evaluation of Brominated Carbazoles as a Novel Antibiotic Adjuvant Scaffold in MRSA.
AID1601157Binding affinity to recombinant human C5a assessed as loss of super secondary structure at > 10 uM incubated for 1 hr at 4 degC by circular dichroism analysis2019Bioorganic & medicinal chemistry, 10-01, Volume: 27, Issue:19
A rational search for discovering potential neutraligands of human complement fragment 5a (
AID1827235Potentiation of oxacillin induced antibacterial activity against methicillin-resistant Staphylococcus aureus USA100 assessed as oxacillin MIC at 50 uM after 18 hrs by CLSI protocol based broth microdilution assay2022ACS medicinal chemistry letters, Mar-10, Volume: 13, Issue:3
Identification and Evaluation of Brominated Carbazoles as a Novel Antibiotic Adjuvant Scaffold in MRSA.
AID1601162Binding affinity to human C5a assessed as induction of conformational change by measuring red shift in absorption maxima at 1 uM by fluorescence analysis2019Bioorganic & medicinal chemistry, 10-01, Volume: 27, Issue:19
A rational search for discovering potential neutraligands of human complement fragment 5a (
AID1079932Highest frequency of moderate liver toxicity observed during clinical trials, expressed as a percentage. [column '% BIOL' in source]
AID1601164Binding affinity to human C5a assessed as Potassium iodide-induced quenching by measuring Stern-Volmer quenching constant at 1 uM by fluorescence analysis (Rvb = 4.1/M)2019Bioorganic & medicinal chemistry, 10-01, Volume: 27, Issue:19
A rational search for discovering potential neutraligands of human complement fragment 5a (
AID274596Increase in beta amyloid protein 38 in human H4 cells overexpressing APP695 at 160 uM2006Journal of medicinal chemistry, Dec-28, Volume: 49, Issue:26
Scaffold of the cyclooxygenase-2 (COX-2) inhibitor carprofen provides Alzheimer gamma-secretase modulators.
AID614601Inhibition of ovine COX-1 assessed as residual activity by measuring formation of 12-HHT from arachidonic acid by HPLC analysis2011Bioorganic & medicinal chemistry, Sep-15, Volume: 19, Issue:18
SAR studies of acidic dual γ-secretase/PPARγ modulators.
AID701504Inhibition of ovine COX1 pre-incubated for 10 mins before arachidonic acid substrate addition by enzyme immunoassay2012Journal of medicinal chemistry, Oct-25, Volume: 55, Issue:20
Identification and characterization of carprofen as a multitarget fatty acid amide hydrolase/cyclooxygenase inhibitor.
AID1507766Inhibition of rat brain FAAH using [3H]AEA as substrate2017European journal of medicinal chemistry, Aug-18, Volume: 136Novel propanamides as fatty acid amide hydrolase inhibitors.
AID1079945Animal toxicity known. [column 'TOXIC' in source]
AID1079937Severe hepatitis, defined as possibly life-threatening liver failure or through clinical observations. Value is number of references indexed. [column 'MASS' in source]
AID362052Antiproliferative activity against human PC3 cells at 100 uM after 72 hrs by MTT assay2008Bioorganic & medicinal chemistry letters, Aug-15, Volume: 18, Issue:16
New NSAIDs-NO hybrid molecules with antiproliferative properties on human prostatic cancer cell lines.
AID1079934Highest frequency of acute liver toxicity observed during clinical trials, expressed as a percentage. [column '% AIGUE' in source]
AID274594Inhibition of beta amyloid protein 42 in human H4 cells overexpressing APP6952006Journal of medicinal chemistry, Dec-28, Volume: 49, Issue:26
Scaffold of the cyclooxygenase-2 (COX-2) inhibitor carprofen provides Alzheimer gamma-secretase modulators.
AID1079946Presence of at least one case with successful reintroduction. [column 'REINT' in source]
AID1079939Cirrhosis, proven histopathologically. Value is number of references indexed. [column 'CIRRH' in source]
AID1601155Binding affinity to recombinant human C5a assessed as conformational change at 1 to 100 uM incubated for 1 hr at 4degC by circular dichroism analysis2019Bioorganic & medicinal chemistry, 10-01, Volume: 27, Issue:19
A rational search for discovering potential neutraligands of human complement fragment 5a (
AID1827147Potentiation of oxacillin induced antibacterial activity against methicillin-resistant Staphylococcus aureus ATCC 43300 assessed as fold change in oxacillin MIC at 25 uM after 18 hrs by CLSI protocol based broth microdilution assay2022ACS medicinal chemistry letters, Mar-10, Volume: 13, Issue:3
Identification and Evaluation of Brominated Carbazoles as a Novel Antibiotic Adjuvant Scaffold in MRSA.
AID1601163Binding affinity to human C5a assessed as loss of secondary structure by measuring red shift in absorption maxima at 10 to 100 uM by fluorescence analysis2019Bioorganic & medicinal chemistry, 10-01, Volume: 27, Issue:19
A rational search for discovering potential neutraligands of human complement fragment 5a (
AID701505Inhibition of human COX2 pre-incubated for 10 mins before substrate addition by enzyme immunoassay2012Journal of medicinal chemistry, Oct-25, Volume: 55, Issue:20
Identification and characterization of carprofen as a multitarget fatty acid amide hydrolase/cyclooxygenase inhibitor.
AID492858Inhibition of human recombinant COX2 after 5 mins2010Journal of medicinal chemistry, Jun-24, Volume: 53, Issue:12
Design, synthesis, and biological evaluation of a novel class of gamma-secretase modulators with PPARgamma activity.
AID701506Inhibition of FAAH in rat brain homogenates pre-incubated for 10 mins before addition of [3H]anandamide and [3H]AEA substrates for 30 mins by liquid scintillation counting2012Journal of medicinal chemistry, Oct-25, Volume: 55, Issue:20
Identification and characterization of carprofen as a multitarget fatty acid amide hydrolase/cyclooxygenase inhibitor.
AID588211Literature-mined compound from Fourches et al multi-species drug-induced liver injury (DILI) dataset, effect in humans2010Chemical research in toxicology, Jan, Volume: 23, Issue:1
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
AID362051Inhibition of COX2 in human whole blood2008Bioorganic & medicinal chemistry letters, Aug-15, Volume: 18, Issue:16
New NSAIDs-NO hybrid molecules with antiproliferative properties on human prostatic cancer cell lines.
AID681027TP_TRANSPORTER: inhibition of PAH uptake (PAH: 20 uM, Carprofen: 1000 uM) in OAT-expressing COS-7 cells1999The Journal of biological chemistry, Jan-15, Volume: 274, Issue:3
Heterologous expression and functional characterization of a mouse renal organic anion transporter in mammalian cells.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID651635Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID1745845Primary qHTS for Inhibitors of ATXN expression
AID504812Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID504810Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID1347159Primary screen GU Rhodamine qHTS for Zika virus inhibitors: Unlinked NS2B-NS3 protease assay2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347160Primary screen NINDS Rhodamine qHTS for Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID504749qHTS profiling for inhibitors of Plasmodium falciparum proliferation2011Science (New York, N.Y.), Aug-05, Volume: 333, Issue:6043
Chemical genomic profiling for antimalarial therapies, response signatures, and molecular targets.
AID1347099qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB1643 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347094qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-37 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347100qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for LAN-5 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347407qHTS to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: primary screen against the NCATS Pharmaceutical Collection2020ACS chemical biology, 07-17, Volume: 15, Issue:7
High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle.
AID1347098qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-SH cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347108qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh41 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347095qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB-EBc1 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347101qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-12 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347096qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for U-2 OS cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1508630Primary qHTS for small molecule stabilizers of the endoplasmic reticulum resident proteome: Secreted ER Calcium Modulated Protein (SERCaMP) assay2021Cell reports, 04-27, Volume: 35, Issue:4
A target-agnostic screen identifies approved drugs to stabilize the endoplasmic reticulum-resident proteome.
AID1347107qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh30 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347091qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SJ-GBM2 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347090qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for DAOY cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347093qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-MC cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347089qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for TC32 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347424RapidFire Mass Spectrometry qHTS Assay for Modulators of WT P53-Induced Phosphatase 1 (WIP1)2019The Journal of biological chemistry, 11-15, Volume: 294, Issue:46
Physiologically relevant orthogonal assays for the discovery of small-molecule modulators of WIP1 phosphatase in high-throughput screens.
AID1347086qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lymphocytic Choriomeningitis Arenaviruses (LCMV): LCMV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347106qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for control Hh wild type fibroblast cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347105qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for MG 63 (6-TG R) cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347103qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for OHS-50 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347097qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Saos-2 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347154Primary screen GU AMC qHTS for Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347092qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for A673 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347425Rhodamine-PBP qHTS Assay for Modulators of WT P53-Induced Phosphatase 1 (WIP1)2019The Journal of biological chemistry, 11-15, Volume: 294, Issue:46
Physiologically relevant orthogonal assays for the discovery of small-molecule modulators of WIP1 phosphatase in high-throughput screens.
AID1347083qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: Viability assay - alamar blue signal for LASV Primary Screen2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347104qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for RD cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347102qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh18 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347082qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: LASV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1345206Human COX-2 (Cyclooxygenase)2011Bioorganic & medicinal chemistry, Sep-15, Volume: 19, Issue:18
SAR studies of acidic dual γ-secretase/PPARγ modulators.
AID1159550Human Phosphogluconate dehydrogenase (6PGD) Inhibitor Screening2015Nature cell biology, Nov, Volume: 17, Issue:11
6-Phosphogluconate dehydrogenase links oxidative PPP, lipogenesis and tumour growth by inhibiting LKB1-AMPK signalling.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (484)

TimeframeStudies, This Drug (%)All Drugs %
pre-199087 (17.98)18.7374
1990's58 (11.98)18.2507
2000's124 (25.62)29.6817
2010's173 (35.74)24.3611
2020's42 (8.68)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 58.38

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be very strong demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index58.38 (24.57)
Research Supply Index6.49 (2.92)
Research Growth Index4.73 (4.65)
Search Engine Demand Index192.08 (26.88)
Search Engine Supply Index3.87 (0.95)

This Compound (58.38)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials142 (27.63%)5.53%
Reviews15 (2.92%)6.00%
Case Studies28 (5.45%)4.05%
Observational0 (0.00%)0.25%
Other329 (64.01%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]